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ABSTRACT OF THE DISSERTATION 
Understanding CRX-Associated Retinopathies  
Using Animal Models 
By 
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Washington University in Saint Louis, 2013 
Professor Shiming Chen, Chair 
 
Cone-rod homeobox (CRX) protein is a “paired-like” homeodomain transcription factor 
that is essential for regulating rod and cone photoreceptor transcription.  Mutations in human 
CRX are associated with the dominant retinopathies Retinitis Pigmentosa (RP), Cone-Rod 
Dystrophy (CoRD) and Leber Congenital Amaurosis (LCA), with variable severity.  The goal of 
my dissertation project was to develop and characterize animal models to understand genetic 
mechanisms of phenotypic diversity in CRX-associated disease.  Heterozygous Crx Knock-Out 
(KO) mice (“+/-“) have normal vision as adults and fail to model the dominant human disease.   
We generated two Crx Knock-IN (K-IN) mouse models: CrxE168d2 (“E168d2”) and CrxR90W 
(“R90W”), which carry distinct types of mutations and are associated with retinopathies of 
differing severity.  As seen in human patients, heterozygous E168d2 (“E168d2/+”) but not R90W 
(“R90W/+”) mice show severely impaired retinal function, while mice homozygous for either 
mutation are blind and undergo rapid photoreceptor degeneration.  Careful morphological and 
biochemical characterization of K-IN mice and their associated mutant CRX proteins reveals 
that they cause disease through distinct molecular mechanisms.  Unexpectedly, we also 
identified that E168d2/+ mice express more mutant CRX protein than wild-type CRX resulting in 
an allelic imbalance favoring the mutant protein.  Characterization of a Crx mutant feline model, 
xii 
 
CrxRdy, in vivo and several Crx mutants in vitro reveals CRX overexpression may be a 
conserved mechanism.  E168d2neo/+, a subline of E168d2 with reduced mutant allele 
expression, displays a much milder retinal phenotype, demonstrating mutant allele expression 
level may be a critical genetic modifier of disease severity.  Our studies indentify genetic 
mechanisms contributing to phenotypic diversity of CRX-associated disease, improve 
understanding of disease pathology and allow for the preliminary testing of novel therapeutic 
approaches.       
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1.1. Establishing functional rod and cone photoreceptors in mammals  
 The first step in forming vision is the conversion of light into an interpretable neurological 
signal.  In the vertebrate retina, the ciliary rod and cone photoreceptors carry out this unique 
task in a process called phototransduction.1  Rods and cones are specially tuned for different 
forms of phototransduction.  Rods are incredibly sensitive, capable of responding to a single 
photon of light, but have slow kinetics.  Rods support dim light and night vision.  Cones are less 
sensitive than rods but have much faster kinetics.  Additionally, many species have multiple 
subtypes of cones with different spectral sensitivities.  Cones support bright light and color 
vision.  To achieve phototransduction, ciliary vertebrate photoreceptors elaborate a highly 
specialized organelle called the outer segment.  Within this organelle are thousands of stacked 
membranes each of which is packed with visual pigment G-protein coupled receptors called 
opsins, which bind a photosensitive chromophore.  The chromophore isomerizes in response to 
light causing a conformational change in the opsin protein which sends a signaling cascade 
through a series of enzymes and proteins leading to the hyperpolerization of the cell.  The large 
surface area of the outer segment and the amplification of the signal confer amazing sensitivity, 
with human rods capable of responding to a single photon of light.  Many of the components of 
the outer segment and the phototransduction pathway are specifically expressed in 
photoreceptors and solely function within this pathway.2  Because of this, the precise regulation 
of photoreceptor gene expression is absolutely critical to their functionality.  
 In mammalian rods and cones, the precise coordination of gene expression is 
dependent on a network of transcription factors (Fig. 1.1).3,4  These transcription factors work in 
concert to activate rod genes in rods, cone genes in cones and repress genes of the opposite 
cell type.  During retinal development, a cascade of transcription factors is expressed in a 
subset of retinal progenitor cells which gives rise to photoreceptors.  In these cells, the 
homeodomain (HD) transcription factor OTX2 activates another HD transcription factor, CRX to 
initiate differentiation along the photoreceptor lineage.  CRX, which is expressed in both 
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developing and mature rods and cones, promotes their terminal differentiation from 
photoreceptor precursors and their long-term survival.  CRX expression is followed by the 
expression of rod-specific (including RORβ, NRL and NR2E3) and cone-specific (including 
RORα, TRβ2, RXRγ and COUP TFs) transcription factors in their corresponding cell types.  
CRX works synergistically with both cell-specific and ubiquitous transcription factors to 
coordinate rod and cone gene expression including the expression of phototransduction  
genes4–8. 
 
1.2. Molecular function of CRX 
CRX (Accession: AAH53672.1) is an Otd/OTX-like ‘paired’ HD transcription factor that is 
preferentially expressed in vertebrate rod and cone photoreceptor cells in the retina and 
pinealocytes in the brain6,7.  CRX plays an essential role in the establishment and maintenance 
of gene expression in mammalian rod and cone photoreceptors9 and the pineal gland10.  The 
molecular function of CRX is highly conserved amongst mammals including humans, mice, and 
cats.6,7,11  Paralogues of CRX/OTX have been found to maintain similar roles in the 
photoreceptors of the evolutionarily divergent vertebrates fish12, amphibians13 and invertebrates 
Drosophila14 and Amphioxus15.  CRX encodes a 299 amino acid protein that contains a 
homeodomain (HD) near its N-terminus that is responsible for DNA binding (Fig 1.2)6,16.  The 
HD is followed by glutamine rich (Gln), basic, WSP and OTX-tail motifs6,16.  Previous studies 
show that CRX binds to photoreceptor target genes7,8,17–23 and can directly activate the 
promoters of target genes in vitro, including its own promoter and Rhodopsin6,18,24,25.  CRX is 
thought to mainly act as a transcriptional activator in photoreceptors based on expression 
profiling of the CRX knock-out (KO) mouse2,3,9, but is associated with repression in certain 
genomic contexts8.  Transactivation activity is dependent on the C terminal region of CRX (from 
the basic to the OTX-tail domains)18.  CRX activates gene expression by interacting with the 
histone acetyltransferases GCN5, CBP and p300 (Accessions: AAC50641.1, AAC17736.1, 
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NP_001420.2, respectively)26, promoting histone acetylation at target gene promoters4,26 and 
mediating enhancer/promoter intrachromosomal looping interactions27 of target photoreceptor 
genes.  These events in chromatin remodeling and transcriptional activation are sequentially 
regulated during retinal development26.  CRX also maintains specific interactions with 
transcriptional co-regulators including the rod-specific transcription factors NRL (Accession: 
NP_006168.1)28,29 and NR2E3 (Accession: AAH41421.1)30,31 to coordinately control 
photoreceptor gene expression.  NRL has been shown to activate rod gene expression32 while 
NR2E3 has dual activator/repressor activity30,33,34.  CRX, NRL and NR2E3 have been shown to 
co-occupy target gene promoters and enhancers in vivo23, have synergistic activity in promoting 
gene expression35.  Genome wide profiling of CRX8 and NRL36 reveal that a high percentage of 
genes bound by NRL are also bound by CRX.  A mouse KO of Nrl causes a fate switch of rods 
to a 'cone-like' state37,38, and the additional loss of CRX in the Crx and Nrl double KO impairs 
the transcription of cone genes in this retina3.  Outside of photoreceptors, CRX was found to 
broadly regulate transcription in the pineal gland39 and loss of CRX attenuated circadian 
entrainment in the mouse9.  These studies suggest that CRX plays a central and critical role in 
the activation of rod and cone gene expression and also regulates gene expression in the pineal 
gland.    
 
1.3. CRX mutations associated with dominant Retinitis Pigmentosa, Cone-Rod Dystrophy 
and Leber Congenital Amaurosis 
Mutations in human CRX (NCBI Reference Sequence: NG_008605.1) have been 
associated with autosomal dominant forms of the retinal degenerative diseases Retinitis 
Pigmentosa (adRP), Cone-Rod Dystrophy (adCoRD) and Leber Congenital Amaurosis (adLCA), 
with different ages of onset and severity29,40–61.  CRX is the only gene associated with all three 
diseases41,43,59,62, demonstrating its central role in rod and cone integrity.  However, null 
Chapter I 
 
5 
 
mutations in CRX may not be responsible for severe dominant disease.  A null mutation in CRX, 
P9ins1, was associated with LCA in a heterozygous patient but the patient’s father, a carrier of 
P9ins1, had a normal ocular phenotype suggesting either recessive or multigenic inheritance60.  
The phenotypes of the human and mouse heterozygous null mutations suggest that 
haploinsufficiency is unlikely to underlie the severe forms of dominant CRX-associated disease. 
Dominant disease-causing human CRX mutations primarily fall into two classes (Fig. 
1.2): frameshift mutations (blue text) mostly in the transactivation domains and amino acid 
substitution mutations (black text) mostly within the DNA binding homeodomain.  Both classes 
are expected to produce mutant forms of CRX protein that are pathogenic.  Supporting this 
hypothesis, the frameshift mutations E168d1, E168d2, G217d1 and several other truncation 
mutations were linked to early onset (0-20 years) severe adCoRD/adLCA40–49,51,53–55,62,63 and 
A196d4 was associated with adult onset adCoRD64.  The substitution mutations, R41W, R41Q, 
R90W and several others were associated with late onset (~40-60 years old) 
adCoRD40,49,53,58,61,62, while K88N was associated with adLCA65.  A patient homozygous for 
R90W was also diagnosed with autosomal recessive LCA61.  Generally, frameshift mutations in 
the transactivation domains of CRX are associated with more early onset and severe dominant 
retinopathies than the substitution mutations, suggesting these two types of mutations may 
represent distinct classes and contribute to the phenotypic diversity of CRX-associated disease. 
1.4. Distinct molecular activity of mutant CRX proteins 
 Most of the frameshift mutations are located in the transactivation domains of CRX (Fig. 
1.2) and lead to the formation of a novel early stop codon typically resulting in the early 
truncation of CRX.  These truncated mutant proteins were predicted to lose transactivation 
activity but maintain DNA-binding activity, since they have an intact homeodomain.  While most 
frameshift mutations are predicted to produce a truncated CRX protein, there are multiple 
mutations which could generate mutant proteins with novel amino acid tails of varying length 
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(summarized in Fig. 1.3).  It is unknown how these unique C-terminal tails affect the function of 
CRX.   
 Truncated CRX proteins resulting from the frameshift mutations E168d1, E168d2, 
A196d4 and G217d1 lost the ability to transactivate the promoter of Rhodopsin (Rho) in 
HEK293 cell transient transfection assays, but are expected to bind DNA normally since CRX 1-
107, a complete activation domain truncation mutant, retained CRX target binding activity18.  It 
was predicted that these truncated mutant proteins could interfere with the function of WT CRX 
by an antimorphic mechanism and cause a severe dominant retinal phenotype18.  Furthermore, 
rescue experiments of the otduvi phenotype in Drosophila demonstrate the CRX truncation 
mutation I138fs48 possessed dominant-negative activity on target gene expression14, providing 
experimental evidence for an antimorphic mechanism for this class of CRX mutations. 
 Four substitution mutations in the homeodomain: R41W, R41Q, R90W28,61,64, and 
K88N29, also reduced the ability of CRX to bind to and transactivate the Rhodopsin promoter.  
R41Q and R90W both reduced CRX:NRL protein interaction28, while K88N additionally 
interfered with basal NRL-mediated transcription65.  R41W, R41Q, and R90W were predicted to 
represent hypomorphic alleles associated with either recessive or less severe dominant forms of 
disease, while K88N was predicted to possess antimorphic activity on NRL function causing a 
stronger phenotype.   In contrast, four other substitution mutations associated with early onset 
adCoRD/LCA: E80A40,49,62,66, A56T47, A158T and V242M58 did not lose DNA binding or 
transactivating activity67.   In vivo rescue experiments in Drosophila also demonstrate that E80A 
but not R90W or K88N possesses some dominant-negative activity on Rh5 expression14.  
Collectively these experiments support our hypothesis that substitution mutations may cause 
disease through several distinct mechanisms.   
 
 
 
Chapter I 
 
7 
 
1.5. Current and proposed models for CRX-associated retinopathy 
 The role of Crx in retinal development was first characterized in vivo by the generation of 
a Crx Knock-OUT (KO) mouse9.  In the homozygous Crx KO mouse (“-/-“), photoreceptors fail to 
form outer segments (OS), a highly specialized photoreceptor organelle which contains visual 
pigment opsins and other proteins required for phototransduction.  As a result, -/- 
photoreceptors do not function, form abnormal synapses, and undergo progressive 
degeneration9,68.  Gene expression profile studies showed that -/- mice have severely reduced 
expression of many photoreceptor specific genes2,3,69.  Most of these genes are direct CRX 
targets as detected by ChIP-seq analyses of the genomic CRX binding profile in the mouse 
retina8. 
 In addition to the Crx KO mouse, the role of CRX and the impact of mutant CRX proteins 
on retinal development has been studied in multiple animal models.  While mouse retinal 
development is guided by a trio of 'paired-like' homeodomain transcription factors OTX1, OTX2 
and CRX6,7,13,70, in Drosophila the roles of these three genes are replaced by a single factor, 
Otd71,72, an paired-like homeobox transcription factor family member.  Human CRX and OTX2 
were able to rescue different aspects of the Otduvi photoreceptor phenotype, suggesting distinct, 
yet overlapping functions for CRX and OTX214.  In addition, it was found that the CRX mutants 
E80A, I138fs48 and R90W had partial and overlapping rescue function on photoreceptor 
morphology and gene expression, while K88N was unable to rescue the Otduvi phenotype.  Of 
these mutations, only E80A and I138fs48 possessed dominant-negative activity, with I138fs48 
having the strongest effect14.  In other studies, a morpholino knockdown of Zebrafish Crx 
showed that CRX was critical for photoreceptor and bipolar cell development12 and lipofection of 
Otx5b, a homologue of Crx, in Xenopus Laevis biased retinal progenitors to the photoreceptor 
fate73.         
 The in vivo studies detailed above have helped to elucidate the roles of CRX and CRX 
homologues in retinal development.  They demonstrate CRX's central role in photoreceptor 
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development and gene expression, which is critical to the formation of functional photoreceptors 
and vision.  However, these animal studies fail to provide accurate models of dominant CRX-
associated retinopathies, limiting their usefulness for translational research.  The heterozygous 
Crx KO mouse (“+/-“), only shows a slight delay in photoreceptor development and largely 
display normal morphology, gene expression and retinal function in adulthood9, suggesting that 
severe dominant disease may result from the activity of mutant CRX proteins.  Supporting this, 
the feline model, CrxRdy, was found to carry a frameshift mutation in Crx, n.546delC, which was 
predicted to generate a truncated CRX protein11.  CrxRdy cats display severe dominant 
impairment of retinal function, photoreceptor degeneration and reduced Rhodopsin expression, 
all characteristic of adLCA74–77.  The phenotype of the CrxRdy cat closely matches human 
retinopathy for similar-type truncation mutations, indicating it is an accurate model of dominant 
CRX-associated disease. 
 
Currently, there is no treatment strategy for CRX-associated diseases.  Establishing 
animal models that accurately recapitulate different disease mechanisms is critical for 
developing and testing novel therapeutic approaches.  The CrxRdy cat demonstrates the 
importance of tailoring animal models to the specific types of mutations identified in human 
patients.  However, the high cost, slow breeding and lack of genetic tools for research in cats, 
are prohibitive for performing advanced pathological and biochemical studies in larger animals.  
Additionally, the CrxRdy cat only represents one type of Crx mutation and human disease is 
associated with multiple distinct types.   
To address these issues, we sought to generate mechanistically distinct mouse models 
of CRX-associated disease to identify specific differences in pathology and molecular function of 
mutant CRX proteins.  Here we report the generation of two Knock-IN (K-IN) mouse models 
carrying different types of human disease-causing Crx mutations and present a detailed 
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morphological, functional and biochemical characterization of these mouse models.  The 
frameshift mutation E168d2 produces a severe dominant phenotype through an antimorphic 
mechanism, while the substitution mutation R90W produces a very mild late-onset ‘CoRD-like’ 
phenotype in heterozygotes and ‘LCA’-like disease in homozygotes.  Furthermore, these studies 
revealed that the expression level of a mutant allele can dramatically affect the disease 
phenotype, providing insight into the phenotypic variability of disease, as well as, potential 
treatment strategies.  
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Fig 1.1) 
 
Figure 1.1) Schematic of the photoreceptor transcription factor network.  CRX works 
synergistically with several co-factors to regulate gene expression in mammalian rods and 
cones.     
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Fig. 1.2) 
 
Figure 1.2) Diagram of CRX protein showing regions associated with DNA binding (green 
box) and transactivation (orange box) and mutations identified from patients with 
retinopathy.  These mutations mainly fall into two classes: amino acid substitutions within the 
DNA binding region (black text) and frameshift deletions and insertions in the transactivation 
region (blue text).  Two mutations (marked by red box) were selected for generating knock-in 
mouse models: E168d2 was predicted to generate a truncated protein that interferes with wild-
type CRX function; R90W was predicted to generate a protein with reduced ability to bind DNA. 
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Fig. 1.3) 
 
Figure 1.3) Schematic representing the predicted size of mutant CRX proteins based on 
genomic sequence analysis.  The specific CRX mutation is listed on the right.  Normal CRX 
coding regions are shown in blue, novel coding regions are shown in red.  A scale bar indicating 
the amino acid (AA) length is shown at the bottom.  
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Introduction- Generation of E168d2 and R90W Knock-IN mouse models 
In this study, we have generated two Crx K-IN mouse lines, each carrying a human 
disease-causing mutation in the mouse allele (Accession: NM_007770.4).  CrxE168d2 (“E168d2”) 
mice carry a 2-bp deletion mutation, Glu168del2, which resulted in a codon frameshift and early 
truncation of the transactivation domains of CRX protein (Fig 1.2, Fig 2.1A-B).  CrxR90W 
(“R90W”) mice carry Arg90Trp, an amino acid substitution mutation in the homeodomain of CRX 
(Fig 1.2, Fig 2.1A-B).  An intermediate subline of each (“E168d2neo” and “R90Wneo”) carrying 
a neomycin (neo) cassette in intron 3-4 was also maintained (Fig 2.1A), since the neo cassette 
specifically reduced the expression of the mutant allele (Fig 2.2).  The neo was removed from 
the germline by crossing E168d2neo and R90Wneo mice to the Sox2-Cre mouse1 to generate 
the final E168d2 and R90W mouse lines (Fig 2.1A).  Successful K-IN was confirmed by PCR 
amplification of neo (Primer set: Neo F/R) and the respective Crx allele (Table 2.1) and Sanger 
sequencing of homozygous mice (Fig 2.1B).  
Results 
2.1. Expression of CRX protein and mRNA in Knock-IN mice  
2.1.i) Mutant CRX protein is overexpressed in E168d2 but not R90W mice   
 To determine if E168d2 and R90W K-IN mice properly express their respective CRX 
proteins, immunofluorescence (IF) staining for CRX was performed on paraffin-embedded 
retinal sagittal sections of P10 mice (Fig 2.2).  The mouse monoclonal CRX antibody M02 
(Abnova) used recognizes WT (Accession: NP_031796.1) and both mutant forms of CRX.  
Slides were immunostained in the same batch and imaged using a common exposure.  As 
reported previously2–4, CRX staining in WT retina (Fig 2.2A) was predominantly localized to the 
outer nuclear layer (ONL), comprised of the rod and cone photoreceptor cell bodies.  Less 
intense CRX staining was also seen in the outer portion of the inner nuclear layer (INL), which is 
comprised of bipolar and horizontal cell bodies.  E168d2 homozygous (E168d2/d2”) and 
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heterozygous (“E168d2/+”) mouse retinas showed higher intensity CRX staining than WT, 
especially in the ONL (Fig 2.2B&C).  The heterozygous E168d2neo (“E168d2neo/+”) retina on 
the other hand showed similar intensity CRX staining as WT retina (Fig 2.2D vs 2.2A).  In 
contrast, CRX staining in the ONL of R90W homozygous (“R90W/W”) and heterozygous 
(“R90W/+”) mouse retinas was reduced compared to WT retinas, although a few cells 
expressing high levels of CRX are scattered across the ONL (Fig 2.2E&F).  This mosaic pattern 
of variable CRX expression was not seen in WT retinas.  Crx Knock-Out (“-/-“) retinas didn’t 
show CRX reactivity in the ONL and served as negative controls (Fig 2.2G). The positive CRX 
staining in E168d2/d2 and R90W/W retinas suggests that the CRX[E168d2] and CRX[R90W] mutant 
proteins were expressed in the appropriate cell layers.  
The expression levels of WT CRX and mutant CRX[E168d2], CRX[R90W] proteins were 
compared and quantified in P10 E168d2 and R90W K-IN retinas using quantitative Western 
blots assayed with the polyclonal CRX 119b-1 antibody5, which also recognized all forms of 
CRX proteins assayed.  WT retina extracts showed a ~37kD band (Fig 2.2H, Lane 1).  In 
contrast, a ~27kD dublet CRX band was detected in E168d2/d2 (Lane 2) and homozygous 
E168d2neo (“E168d2neo/d2neo”) (Lane 3) retinas, suggesting that the CRX[E168d2] protein was a 
truncated CRX protein as predicted by Sanger sequencing and genomic alignment (Fig 2.1B).  
Furthermore, the band intensities suggest that the amount of CRX[E168d2] protein in mutant 
retinas is higher than that of the full-length CRX in WT retinas (Fig 2.2H, Lanes 2&3 vs. Lane 1).  
Quantification of CRX protein levels (Fig 2.2I) revealed a significant genotype difference 
(p=0.0002) overall.  E168d2/d2 retinas made twice as much total CRX protein as WT retinas, 
while E168d2neo/d2neo retinas produce similar amounts of CRX protein as WT retinas.   
Heterozygous E168d2/+ (Fig 2.2H, Lane 4) and E168d2neo/+ (Lane 5) mice expressed 
both full-length WT CRX and truncated CRX[E168d2] protein but in different ratios.  Quantification 
of CRX protein in E168d2/+ retinal extracts (Fig 2.2I) revealed that the full-length WT CRX 
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protein was present at approximately half of the level in WT retinas, but the level of CRX[E168d2] 
protein was more than twice that of the WT CRX.  As a result, the total CRX protein level in 
these retinas was significantly increased by 2-fold compared to normal retinas.  E168d2neo/+ 
retinal extracts also expressed WT CRX at approximately half WT levels but expressed less 
CRX[E168d2] protein than E168d2/+ retinas (Fig 2.2H, lane 5 vs. 1&4, and Fig 2.2I).  As a result, 
the total CRX level in E168d2neo/+ was comparable to the WT control levels.  These results are 
consistent with immunostaining results shown in Fig 2.2B-D and suggest that the E168d2 allele 
overproduces mutant protein, which was prevented by the presence of the neo cassette in 
E168d2neo.   
CRX expression patterns in R90W mice differed from E168d2.  In P10 R90W/W retinal 
extracts (Fig 2.2H, Lane 6, & Fig 2.2I), CRX[R90W] was not significantly different from CRX in WT 
retinal extracts (Fig 2.2H, Lane 1, & Fig 2.2I), while levels were reduced in R90Wneo/Wneo 
retinas (Fig 2.2H, Lane 7 & Fig 2.2I).  R90W/+ retinas (Fig 2.2H, Lane 8, & Fig 2.2I) had normal 
total CRX protein levels compared to WT mice, although it was not possible to distinguish the 
quantity of WT CRX vs. CRX[R90W].  As seen with the E168d2 allele, the presence of the neo 
cassette reduced total CRX protein levels in R90Wneo/Wneo and R90Wneo/+ retinas, 
compared to corresponding R90W retinas (Fig 2.2H, Lane 7 vs. 6, Lane 9 vs. 8, & Fig 2.2I).  
Thus, the presence of the neo cassette similarly affected the expression of both K-IN alleles.   
 
2.1.ii) Mutant Crx mRNA is overexpressed in E168d2 but not R90W mice   
To investigate whether the changes observed in CRX protein levels correlate with 
altered Crx mRNA transcription, Crx mRNA levels were determined by quantitative real-time 
reverse transcriptase PCR (qRT-PCR) (Fig 2.2J).  Specific PCR primer pairs were used that 
selectively amplified sequences from either WT or total (WT+mutant) Crx cDNA (Primer sets: 
Crx E168WT F/R and Crx R90WT F/R; Table 2.1).  Primer specificity was validated by 
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amplification of WT, E168d2/d2 and R90W/W retinal cDNA preparations.  The results show that 
E168d2/d2 retinas made twice as much total Crx mRNA as WT retinas, consistent with the 
elevated CRX protein levels in E168d2/d2.   Total Crx mRNA levels in E168d2neo/d2neo retinas 
were lower than E168d2/d2 levels (FDR p=0.07) but remained elevated relative to the WT 
(p<0.05) retinas, in contrast to the normal total CRX protein levels observed in these retinas.   
E168d2/+ mice also showed moderately elevated total Crx mRNA levels (Fig 2.2J).  
Similar to protein levels, E168d2 mRNA levels (deduced from Total - WT) were much higher 
than WT levels (~2:1 ratio).  By comparison, E168d2neo/+ mice expressed slightly elevated 
levels of total Crx mRNA that were lower than E168d2/+.  WT and E168d2 alleles were evenly 
expressed in these retinas.  These results are consistent with the differences in CRX protein 
levels, supporting an RNA-based mechanism for CRX[E168d2] overexpression, which was partially 
reversed in E168d2neo/+ mice.   
R90W mice showed a distinct pattern of mRNA expression compared to E168d2.   
R90W/W retinas had normal Crx mRNA levels (Fig 2.2I), in contrast to their reduced CRX 
protein levels.  This suggests a post-transcriptional mechanism either in the production or 
degradation of CRX[R90W] protein is likely responsible.  Crx mRNA levels in R90Wneo/R90Wneo 
mice were substantially reduced in comparison to WT (p<0.05) and R90W/R90W mice (FDR 
p=0.07).  The R90W/+ and R90Wneo/+ mice showed essentially normal levels of total Crx 
mRNA, contributed either by both alleles equally (in R90W/+) or the WT allele predominantly (in 
R90Wneo/+).  Together, our results suggest that E168d2 and R90W mRNA and corresponding 
proteins are produced in K-IN mouse retinas, but expression levels are differentially regulated.  
The mechanism of differential expression appears to be determined by features intrinsic to each 
mutant allele.    
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2.2. Retinal morphology 
 
2.2.i) Morphology of homozygous Knock-IN mice   
To determine the effect of E168d2 and R90W mutations on retinal morphology, paraffin 
embedded retinal sections from E168d2/d2 and R90W/W mice at P14, 1 month (mo) and 3mo 
were stained with hematoxylin and eosin (H&E), imaged by light microscopy and compared to 
sections from WT and -/- mice6,7 (Fig 2.3).  Cell specification in WT retina is complete by P14 
and three distinct neuronal layers are present: the ONL, INL and the ganglion cell layer (GCL) 
(Fig 2.3A).  At P14 E168d2/d2, R90W/W and -/- retinas all had established normal cellular 
lamination (Fig 2.3B-D).  Quantitative morphometric measures across the sagittal plane of the 
retina presented by ‘spider graphs’ (Fig 2.3M) did not show a genotype*distance interaction (the 
statistical threshold required to make individual comparisons when analyzing data with two-way 
ANOVA) (p=0.15) at P14.  These results support previous finding that CRX is not required for 
retinal cell fate specification6, including rod photoreceptors, which constitute the majority of cells 
in the ONL.  However, unlike WT retinas none of the mutant ONL cells had begun to form OS’s 
at this age (Fig 2.3B, C, D vs. A).  This OS defect persisted through 1-3mo when OS's were fully 
formed in WT retina (Fig 2.3F, G, H vs. E; J, K, L vs. I).  By 1 mo, loss of ONL nuclei was 
evident in all mutant retinas (Fig 2.3F-H).  In comparison to the ~12 rows of ONL nuclei seen in 
WT retinas, E168d2/d2 had only ~3-4 rows, and R90W/W and -/- had ~7-9 rows (Fig 2.3F, G, H 
vs. E).  Quantification of ONL thickness shows photoreceptor degeneration occurred evenly 
across the sagittal plane of all mutant retinas (Fig 2.3N, red, green & blue lines vs. black).  
While R90W/W and -/- mice had similarly reduced ONL thickness (green and blue line, 
respectively), E168d2/d2 retinas showed greater ONL thinning at 1mo (red line vs. green & 
blue), suggesting that degeneration was accelerated in these retinas.  At 3mo, all models 
exhibited greatly reduced ONL thickness (Fig 2.3O) with only ~2-3 rows of ONL cells remaining 
(Fig 2.3J, K, L vs. I), suggesting ONL degeneration is progressive and extensive in all 
homozygous mutant mice. 
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 To determine if ONL thinning is mediated by programmed cell death, “terminal 
deoxynucleotidyl transferase dUTP nick end labeling” (TUNEL) analysis was performed on P21 
and P35 sagittal retinal sections (Fig 2.4).  At P21 (Fig 2.4A-E), E168d2/d2, R90W/W and -/- 
mice all had significantly increased TUNEL+ cells present, almost exclusively in the ONL, 
E168d2/d2 exhibited the highest number of TUNEL+ cells (~34 fold over WT).  At P35 (Fig 2.4F-
J), TUNEL+ cells remained elevated in the ONL of all mutant models but E168d2/d2 mice 
showed fewer TUNEL+ cells compared to R90W/W and -/- mice.  There was no increase in 
TUNEL+ cells in other retinal layers of any of the mutant mice.  These timecourse analyses 
suggest that the peak of ONL degeneration is earlier in E168d2/d2 mice compared to R90W/W 
and -/- mice, corresponding with the earlier ONL thinning observed in morphometric analyses.  
 In spite of reduced Crx expression levels, homozygous mice from the sublines of each 
strain that carry a neo cassette (E168d2neo/d2neo, R90Wneo/Wneo) displayed retinal 
morphology and function (data not shown) that was indistinguishable from the respective neo-
deleted line.  Thus, in homozygous mice lacking WT alleles, the onset and rate of photoreceptor 
degeneration was not greatly affected by mutant protein expression level. 
 
2.2.ii) Rod morphology and survival in heterozygous Knock-IN mice  
 To determine the inheritance of E168d2 and R90W-associated phenotypes, retinal 
morphology of heterozygous E168d2/+, E168d2neo/+ and R90W/+ mice was assessed by 
histology and morphometry.  Paraffin embedded sagittal retina sections of heterozygous mutant 
mice at P14, 1mo, 3mo and 6mo were stained with H&E, imaged by light microscopy and 
compared to WT sections (Fig 2.5A-P).  At P14, all retinas of heterozygous mutant mice 
displayed normal cellular lamination (Fig 2.5B-D vs. A).  However, morphometric measurements 
of the ONL thickness showed that E168d2/+ had increased thickness at the two points most 
proximal to the optic nerve head (ON) (Fig 2.5Q, colored lines vs. black).  E168d2/+ retinas also 
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showed shortened rod OS’s compared to WT (Fig 2.5B vs. A).  The OS defect in E168d2/+ 
retinas remained at 1mo (Fig 2.5F vs. E), 3mo (Fig 2.5J vs. I) and 6mo (Fig 2.5N vs. M).  At 
1mo and 3mo (Fig 2.5E-L, R-S), morphometric measurements of ONL thickness did not identify 
a significant genotype*distance interaction overall, therefore differences at each distance were 
not tested.  However, at 3mo, E168d2/+ had fewer rows of ONL cells ~6-8 and had reduced 
mean ONL thickness at each distance.  By 6mo, most of E168d2/+ ONL cells had degenerated 
with only ~2-3 rows of nuclei remaining (Fig 2.5N vs. M; Fig 2.5T, red vs. black line).  By 
morphometric analyses, E168d2/+ exhibited reduced ONL thickness at all distances. These 
results suggest that E168d2/+ retinas undergo progressive rod photoreceptor degeneration 
through 6mo of age.  Consistent with this observation, TUNEL analysis showed at P35 
E168d2/+ mice had 15-fold more TUNEL+ cells than WT all of which were located in the ONL 
(Fig 2.4L vs. K; Fig 2.4O), consistent with the observed photoreceptor degeneration phenotype.  
These results suggest that the E168d2 mutation causes dominant rod photoreceptor 
morphological defects and degeneration.    
 To determine if mice expressing lower levels of CRX[E168d2] protein have a less severe 
retinal phenotype, the morphology of E168d2neo/+ retinas was compared with that of E168d2/+ 
retinas.  At P14, similar to E168d2/+ (Fig 2.5B), the OS’s of E168d2neo/+ mice appeared 
shorter than in WT mice (Fig 2.5C vs. A).  However, unlike E168d2/+, E168d2neo/+ formed fully 
elongated outer segments by 1mo (Fig 2.5G vs. F), which were well maintained at 3mo (Fig 
2.5K vs. J) and 6mo (Fig 2.5O vs. M).  These results suggest that, despite a delay in maturation, 
E168d2neo/+ mice had less disrupted rod photoreceptor structure than E168d2/+.  Furthermore, 
E168d2neo/+ did not show significant thinning of the ONL through 6mo (Fig 2.5S&T, blue vs. 
black line) or elevated TUNEL+ cells compared to WT (Fig 2.4 M vs. K).  Overall, the rod 
photoreceptor phenotype of E168d2neo/+ mice is mild compared to E168d2/+ mice, suggesting 
that E168d2 disease severity was influenced by the expression level of the mutant allele in 
heterozygous mice, consistent with E168d2 being an antimorphic mutation. 
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 To further reveal morphological defects in E168d2 photoreceptors at the ultra-structural 
level, transmission electron microscopy (TEM) imaging analyses were performed on the retinas 
of P21 E168d2/+, E168d2neo/+ and WT mice (Fig 2.5U-W).  Images were randomly coded for 
blinded data analysis.  Compared to the morphology of WT OS's (Fig 2.5U), E168d2/+ mice (Fig 
2.5V) exhibited severely shortened and disordered OS's including the presence of ‘wave-like’ 
disc patterns (white ‘*’s), ectopic vesicle formation (white ‘+’s), and improper stacking of OS 
discs including vertically oriented discs (white triangles).  OS morphology was largely normal in 
E168d2neo/+ mice (Fig 2.5W); although minor ‘wave-like’ disc patterns and ectopic vesicle 
formation were occasionally seen.  
Rod nuclei in P21 WT retina adopt a characteristic nuclear architecture with large areas 
of highly electron dense heterochromatin in the center and smaller regions of translucent 
euchromatin in the nuclear periphery8 (Fig 2.6A&D).  The chromatin pattern of E168d2/+ rods, 
however, appeared less condensed than WT (Fig 2.6B&E vs. A&D).  This did not occur in 
E168d2neo/+ mice (Fig 2.6C&F vs. A&D).  To quantify these changes, the percentage of the 
nuclear area comprised of condensed heterochromatin was measured in randomly selected 
WT, E168d2/+ and E168d2neo/+ rod nuclei.  Fig 2.6G shows that the mean area of 
heterochromatin in E168d2/+ rods was significantly reduced by 8% compared to WT.  This 
reduction in rod heterochromatin territory was not seen in E168d2neo/+ mice, suggesting more 
normal rod nuclear architecture.  In addition, photoreceptor degeneration in E168d2/+ and 
E168d2neo/+ mice was evidenced by the presence of highly electron dense nuclei 
corresponding to pyknotic photoreceptor cells undergoing cell death, which were not observed 
in WT retinas (Fig 2.6E&F vs. G, white pentagon). 
 Unlike E168d2/+, R90W/+ mice had normal retinal morphology at all ages (Fig 2.5D, H, 
L&P), comparable to +/- mice6.  They formed and maintained full-length OS’s and normal ONL 
thickness (Fig 2.5H, L&P) through 6mo of age.  No increase in TUNEL+ cells over WT was 
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detected (Fig 2.4N&O).  These results suggest rod photoreceptor development and 
maintenance are normal in R90W/+ mice.  This is consistent with clinical evaluations for 
heterozygous R90W carriers in human cases9–13. 
 
 
2.2.iii) Cone morphology and survival in heterozygous Knock-IN mice  
 
2.2.iii.a) Mislocalization of cone nuclei in heterozygous E168d2 mice  
Cone photoreceptors comprise only ~3% of ONL cells in mouse retina and their integrity 
could not be accurately assessed by light microscopy-based histology alone.  However, cone 
nuclei were identified in TEM micrographs by their distinct decondensed chromatin patterns8 
and their nuclear position near the outer edge of the ONL (Fig 2.6A, white arrows).  In the 
retinas of P21 E168d2/+ mice, few cone nuclei were identifiable in the ONL (Fig 2.6B&E).  The 
majority of nuclei with ‘cone-like’ decondensed chromatin were misplaced to the inner regions of 
the ONL adjacent to the OPL (Fig 2.6E, white arrows).   
The number of identifiable cone nuclei in E168d2neo/+ mice was greatly increased 
compared to E168d2/+, but nuclei were frequently mislocalized to the middle and inner ONL 
(Fig 2.6F, white arrows).  Thus, cone formation/survival is improved in E168d2neo/+ mice but 
cone nuclear localization remains abnormal.  Taken together, the ultra-structural analyses 
suggest that rod and cone photoreceptor morphology is highly disrupted in E168d2/+ mice, and 
less so in E168d2neo/+ mice.   
  To determine whether the scattered nuclei with decondensed ‘cone-like’ chromatin in 
E168d2/+ and E168d2neo/+ were indicative of mislocalized cone nuclei, cone specific markers 
were used to further assess the cell population.  Paraffin-embedded retinal sections were 
immunostained for cone arrestin (CARR, Accession: Q9EQP6.1) (antibody: rabbit polyclonal α-
mCARR, Millipore), which stained the cone cell body from the inner segment to the synaptic 
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terminal (Fig 2.7A-D).  Normal cones undergo nuclear migration during development, reaching 
their final position at the apical ONL by P1214,15.  Retinal sagittal sections immunostained with 
CARR were analyzed to determine cone nuclear position in WT and mutant retinas (Fig 2.7A-
D).  Nuclei were assigned to three zones: Inner (IONL), Mid (MONL) or Outer ONL (OONL) (Fig 
2.7A).  At P14, while most WT cone nuclei were positioned in the OONL, cone nuclei in 
E168d2/+ were mostly (>70%) positioned in the IONL and the majority of E168d2neo/+ cone 
nuclei (~70%) were mislocalized in the MONL (Fig 2.7E).  At 1mo, E168d2/+ cone nuclei 
remained highly scattered (Fig 2.7B, white arrow) with less than 20% localized to OONL (Fig 
2.7F), while most E168d2neo/+ cone nuclei (~80%) had migrated to the OONL although a 
significant number (11%) remained in the MONL (Fig 2.7C white arrows; Fig 2.7F).  Thus, cone 
nuclear migration was largely ablated in E168d2/+ mice, while this phenotype was less severe 
in E168d2neo/+ mice.  In contrast, cone nuclei localization in R90W/+ retina was mildly affected 
at P14 (~17% in MONL) (Fig 2.7E) but was normal at 1mo of age (Fig 2.7D&F).  
 
2.2.iii.b) Progressive cone degeneration in heterozygous E168d2 mice  
The numbers of CARR+ cones in P14 and 1mo E168d2/+ retina sections were 
noticeably reduced compared to WT retina (Fig 2.7B).  This could have been caused by either 
missing cone photoreceptors or aberrant CARR expression.  Indeed, the expression of CARR 
was previously shown to be CRX-dependent6 and was reduced in E168d2/+ and E168d2neo/+ 
retinas (see below).  To accurately determine the integrity of the cone population in 
heterozygous mutant retinas, another pan cone marker, peanut agglutinin conjugated to 
Rhodamine (PNA, Vector labs) was used in immunofluorescence staining of whole-mount 
retinas (Fig 2.8).  Unlike CARR, PNA reactivity was independent of CRX’s regulatory function 
and marked the membrane sheath of all cones16, thus allowing for the accurate assessment of 
cone density in mutant retinas.  Whole-mount retina preparations of 1mo and 1year (yr) old 
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heterozygous K-IN mice were stained with PNA (Fig 2.8E-L, blue stain).  40x fluorescent images 
were taken of the dorsal (D), ventral (V), nasal/temporal (N/T) and central (C) retina 
(diagrammed in Fig 2.8A), and cone density from each region was determined by counting 
PNA+ cells.  At 1 mo, total cone density from E168d2/+ retinas over all regions was reduced by 
67.7±1.3% (Fig 2.8B&C, green vs. blue bars), suggesting a cone deficit prior to rod 
degeneration.  Cone density in 1yr old E168d2/+ retinas was not determined because ONL 
degeneration was already extensive by 6mo (Fig 2.5N).  Cone density was preserved in 
E168d2neo/+ mice at 1mo but was reduced by 39.6±5.3% at 1yr (Fig 2.8B, red vs. blue bar in 
each age group).  Further comparing the cone density in different regions of E168d2neo/+ retina 
showed that cone density was normal in all regions at 1mo (Fig 2.8C, red vs. blue bars) and in 
the ventral retina at 1yr of age, but was reduced in all other regions (Fig 2.8D, red vs. blue 
bars).  These results suggest that E168d2/+ mice had early cone deficits, while cones were 
maintained longer in E168d2neo/+ retinas.  In contrast, R90W/+ mice had normal overall cone 
density through 1yr (Fig 2.8B&C, purple vs. blue bars), despite modestly reduced cone density 
in the central region with age. 
 
2.2.iiic) Malformation of M/S cone opsin gradient in heterozygous E168d2 mice 
 Mouse cones consist of three subtypes defined by which cone opsins they express: 
OPN1MW (MOP, Accession: NP_032132.1), OPN1SW (SOP, Accession: NP_031564.1) or 
both opsins.  In normal mouse retina, MOP and SOP are expressed in opposing gradients along 
the dorsal-ventral axis17.  In the dorsal retina, a high percentage of cones express MOP, a few 
cones express SOP and no cones express both.  Moving towards the central and ventral retina, 
there is an increase in SOP and MOP/SOP co-expressing cones18.  The formation of the cone 
opsin gradient in Crx mutant retinas was assessed by IF staining of whole-mount retinas with 
polyclonal rabbit anti-red/green opsin (Millipore), polyclonal goat anti-OPN1SW (Santa Cruz) 
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antibodies and PNA.  Fluorescence images acquired in the regions diagrammed in Fig 2.8A of 
control WT retinas showed the clear formation of the cone opsin gradient as expected (Fig 2.8E 
& I).   
At 1mo, E168d2/+ mice had low levels of the cone opsins in their outer segments and 
did not establish the M/S opsin gradient properly (Fig 2.8F&J).  This conclusion was confirmed 
by quantification of the fraction of cones (PNA+) expressing MOP, SOP, both opsins or no opsin 
in tested regions (Fig 2.8M-P).  E168d2/+ dorsal retina showed a reduction in the proportion of 
cones expressing MOP only, but an increase in cones expressing SOP or both opsins (Fig 2.8 
F&M, E168d2/+ vs. WT).  In contrast, E168d2/+ ventral retina showed a large decrease in the 
percentage of MOP/SOP co-expressing cones and an increase in cones expressing SOP only 
(Fig 2.8J&P, E168d2/+ vs. WT).  Changes in M/S opsin patterns in central and nasal/temporal 
regions were also seen in E168d2/+ mice (Fig 2.8N&O, E168d2/+ vs. WT).  Overall, E168d2/+ 
mice had a lower percentage of co-expressing cones and failed to properly regulate opsin 
expression across the dorsal-ventral axis.  In addition, the levels of opsin on individual cone 
outer segments were highly variable in E168d2/+ retinas, and some PNA+ cells did not have 
any detectable opsin (Fig 2.8F&J, white arrows).  These results suggest that cone opsin 
expression, trafficking, or both were affected in E168d2/+ retina.   
In contrast, the levels of MOP and SOP were closer to normal in E168d2neo/+ cones but 
the opsin gradient remained highly disrupted (Fig 2.8G&K vs. E&I).  As shown in the bar graphs, 
the percentage of cones co-expressing MOP/SOP was increased dramatically in E168d2neo/+ 
dorsal retina (Fig 2.8M, E168d2neo/+ vs. WT), while the percentage of co-expressing cones 
was decreased in the central, nasal/temporal and ventral retina (Fig 2.8N-P, E168d2neo/+ vs. 
WT).  These results suggested that in E168d2neo/+ retinas, despite having normal cone 
numbers at 1mo, the cone opsin gradient was not properly established, which may have 
contributed to the deficits in cone function (see below) and long-term survival.   
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By comparison, R90W/+ mice showed largely normal M/S opsin expression and gradient 
formation across the dorsal to ventral retina (Fig 2.8H&L vs. E&I).  Quantification did not reveal 
any significant differences in the fraction of cones expressing each opsin in any of the regions 
surveyed (Fig 2.8M-P, R90W/+ vs. WT).    
 Taken together, assessment of the cone photoreceptor population in mutant mice 
reveals that cones do not develop properly in E168d2/+ retinas and cone defects arise earlier 
and are more severe than rod defects.  E168d2neo/+ retinas showed more normal cone 
photoreceptor development and morphology and slower cone degeneration than E168d2/+ 
retinas.  However, cone subtype specification remained disrupted in E168d2neo/+ retinas.  
Reduction in the number of cones in E168d2/+ and E168d2neo/+ before rod degeneration was 
consistent with a ‘cone-centric’ phenotype.  In contrast, R90W/+ mice had largely normal cone 
morphology, did not exhibit any significant cone subtype differences and no changes in overall 
cone density through 1yr.   
2.3. Retinal physiology in E168d2 and R90W K-IN mice 
 
2.3.i) Homozygous Crx E168d2 and R90W mice are functionally blind 
 
 To assess the consequence of these morphological changes on retinal function, 
electroretinograms (ERG) were performed under various light intensities on WT, E168d2/d2 and 
R90W/W mice at 1 month of age19.   E168d2/d2 and R90W/W mice did not show any detectable 
dark-adapted or light-adapted responses (Fig 2.9 A-C).  These results suggest E168d2/d2 and 
R90W/W mice are blind at young ages, similar to the phenotype reported for -/- mice6.  The 
functional deficits of rod and cone photoreceptors in E168d2/d2 and R90W/W mice are 
consistent with the necessity of photoreceptor OS’s for phototransduction20,21 and suggest 
defective development of photoreceptor function in the homozygous mutant mice, similar to 
deficits in retinal function in LCA patients. 
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2.3.ii) Retinal function in heterozygous Knock-IN mice 
 
2.3.i.a) Heterozygous E168d2 mice show severe rod/cone functional deficits 
 To determine if rod and cone photoreceptor morphological abnormalities and 
degeneration correspond with impaired retinal function, ERG’s were performed on E168d2/+, 
E168d2neo/+, R90W/+, and +/- mice at 1mo, 3mo and 6mo (Fig 2.9D-L).  First, ERG analyses 
were carried out on dark-adapted animals to assess rod-driven function.  The responses to light 
flashes of increasing intensities were recorded, and the amplitudes of the A-waves (arising from 
the hyperpolarization of photoreceptors) and B-waves (arising from the activity of the 
photoreceptor-driven inner retina)19 were measured.  The results were plotted as average peak 
amplitudes of A and B-waves, against serial log scale light intensities (Fig 2.9D, E, G, H, J & K, 
black line).  Next, ERGs were performed after 10 minutes of light adaptation to measure cone-
driven responses.  The average peak amplitudes of light-adapted B-waves were plotted against 
log scale light intensity (Fig 2.9F, I & L, black line).  A significant genotype*light flash intensity 
interaction (by two-way ANOVA, p<0.05) was detected at every time point for both dark and 
light-adapted tests.  At 1 mo, both dark-adapted A and B-waves were detectable in E168d2/+ 
mice particularly in high light intensities, but the peak amplitudes were significantly reduced 
compared to WT controls (Fig 2.9D&G, green vs. black line), indicating impaired “rod-driven” 
function.  E168d2/+ rod function declined further with age, as the peak amplitudes became 
progressively smaller at 3 mo and 6 mo (Fig 2.9G, J vs. D; H, K vs. E, green line), 
corresponding with rod degeneration.  For illustrative purposes, the progressive nature of rod 
functional deficits was demonstrated by the mean percent reductions of dark-adapted A and B-
wave amplitudes (Table 2.2, E168d2/+ columns).  Percent reduction for both A and B-waves 
increased from 1mo to 6mo suggesting further deviation from WT function.     
Cone-driven light-adapted B-wave peak amplitudes were barely detectable in E168d2/+ 
at 1 mo (Fig 2.9F, green line) and all later ages tested (Fig 2.9I&L, green line), corresponding 
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with the early reduction of cone number.  The mean percent reductions in light-adapted B-wave 
amplitudes were more severe than those seen in dark-adapted A or B-wave amplitudes (Table 
2.2, E168d2/+ columns), suggesting that cone function was more severely affected than rod 
function in E168d2/+ mice.    
 Compared to E168d2/+, E168d2neo/+ mice show significantly less impaired dark-
adapted A and B-wave peak amplitudes for most light intensities at all the ages tested (Fig 
2.9D, E, G, H, K & L, red line vs. green line).  E168d2neo/+ mice only had minor ‘rod-driven’ 
functional deficits compared to WT mice (red line vs. black line).  These findings are 
summarized in Table 2.2.  The average percent reductions of the dark-adapted A and B-waves 
in E168d2neo/+ mice were much less than E168d2/+ for all three ages tested.  More 
importantly, the minor deficits in E168d2neo/+ ‘rod-driven’ function did not progress with age, 
consistent with improved rod survival.  Light-adapted B-waves were also significantly more 
robust in E168d2neo/+ mice, compared to E168d2/+ mice (Fig 2.9F, I & L, red vs. green line), 
but remained significantly reduced, compared to WT mice (red vs. black line).  E168d2neo/+ 
cone deficits were more severe than rod deficits as shown by higher percent reductions in light-
adapted B-waves than dark-adapted B-waves (Table 2.2, E168d2neo/+ columns).  These 
defects were first detected at 1mo and persist through 6mo.  Thus, while E168d2/+ mice had 
severely impaired rod and cone function resembling an ‘LCA’ phenotype, E168d2neo/+ mice 
had ‘cone-centric’ deficits in retinal function, modeling a ‘CoRD’ phenotype.  The ‘cone-centric’ 
morphological and functional deficits of E168d2neo/+ mice, together with the early cone deficits 
in E168d2/+ mice, suggest that cones may be more sensitive than rods to the antimorphic effect 
of CRX[E168d2] protein.   
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2.3.ii.b) Heterozygous R90W mice show minor late-onset cone functional deficits  
Previous studies report subtle ERG deficits in +/- mice6, but in our studies R90W/+ and 
+/- mice did not show significant ERG deficits at 1mo or 3mo (Fig 2.9D-I, blue and orange line, 
respectively).  At 6mo, R90W/+ mice exhibit minor light-adapted B-wave deficits at the 1.88, 
2.39 and 2.82 cdS/m2 flash intensities (Fig 2.9L, blue vs. black line), while +/- were functionally 
normal, suggesting late-stage cone defects in R90W/+ mice.  The difference between our 
studies and previous studies on +/- could have been due to mouse strain background, since the 
original Crx KO characterization was performed on a mixed background of 129Sv x C57BL/66.  
All experiments in this paper were performed on a congenic C57BL/6J background.  
Nevertheless, the R90W mutation produced only a mild late-stage cone functional phenotype in 
heterozygous mice, while the E168d2 mutation in heterozygous mice caused an early-onset 
severe impairment of rod and cone function that depended on the expression level of the 
E168d2 allele relative to WT.   
 
2.4. Molecular activity of CRX[E168d2] and CRX[R90W] proteins 
 To determine how mutant forms of CRX protein affect target gene transcription, we 
assessed their ability to bind to DNA and transactivate transcription.  First, electrophoretic 
mobility shift assays (EMSA) were used to measure DNA binding activity of CRX WT, 
CRX[E168d2] and CRX[R90W] protein expressed in HEK293 cells on the rhodopsin promoter target 
site BAT-122 (Fig 2.10A).  To compare relative binding affinity, the amount of CRX in each 
nuclear extract was quantified using Western blots and equalized between transfections (Fig 
2.10B).  EMSA was then performed on a 2-fold dilution series of nuclear extracts of each CRX 
protein.  Following incubation with BAT-1 probe, WT CRX extract produced a single species of 
specific band shift (marked as ‘WT’) with a concentration-dependent intensity.  This shifted band 
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represented specific binding of the indicated CRX protein to BAT-1 CRX sites, as it is absent in 
the lane receiving the GFP control extract and when the probe contains mutated CRX binding 
sites (BAT-1 Mut AB).  CRX[E168d2] nuclear extract also produced a specific band shift (marked 
‘E168d2’), which migrated much faster than the full-length CRX band as expected for a 
truncated protein.  The intensity of the E168d2 band was comparable to the WT full-length band 
at each corresponding concentration, suggesting that CRX[E168d2] binds target sites with similar 
efficiency as WT CRX, providing a basis for competition binding to common targets.  In contrast, 
CRX[R90W] nuclear extract produced a faint band with the same mobility as WT (Fig 2.10A), but 
significantly reduced intensity (~69% lower than WT).  Reduced but not abolished DNA binding 
activity was also reported for bacterially expressed CRX homeodomain peptides carrying the 
R90W mutation23.  These results support the hypothesis that CRX[E168d2] protein maintains 
normal DNA binding ability, while CRX[R90W] protein has reduced DNA binding ability.  
 To determine if in vitro DNA binding activity of each mutant reflected ability to associate 
with target chromatin in vivo, the association of WT CRX, CRX[E168d2] and CRX[R90W] protein with 
target gene promoter regions was examined using chromatin immunoprecipitation (ChIP) 
assays.  ChIP was performed on P10 mouse retinas of WT, E168d2/d2, R90W/W and -/- mice 
using the CRX 119b-1 antibody5.  As expected, enrichment of CRX[E168d2] protein was detected 
on the promoter of genes expressed in rods (Rho, Gnat1), cones (Arr3, Opn1mw, Opn1sw) and 
both rods/cones (Crx, Rbp3 (Accession: AJ294749.1)) (Fig 2.10C, red bars).  Despite reduced 
DNA binding activity in vitro, CRX[R90W] protein was found on the promoter of all candidate genes 
tested (Fig 2.10C, green bars).  The mechanism by which CRX[R90W], which has reduced DNA-
binding ability, is recruited to target gene chromatin in vivo remains to be determined.   
 The ability of CRX[E168d2] and CRX[R90W] proteins to transactivate target promoters, either 
alone or in combination with WT CRX, was assessed by dual-luciferase reporter assays in 
transiently transfected HEK293 cells.  Consistent with a previous report23, WT CRX was able to 
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cooperate with NRL to activate a Rhodopsin promoter-driven luciferase reporter, Br130 (Fig 
2.10D).  However, CRX[E168d2] failed to increase transactivation above NRL alone, suggesting 
that CRX[E168d2] was unable to form functional interactions with transcription co-activators despite 
its normal DNA binding ability.  In contrast, CRX[R90W] weakly promoted NRL-mediated 
transactivation, consistent with CRX[R90W]’s weak ability to bind target DNA (Fig 2.10A) and 
interact with NRL24 in vitro.  To test the effect of mutant protein on WT CRX function, E168d2 
and R90W expression vectors were each co-transfected at increasing concentrations with WT 
CRX.  CRX[E168d2] protein significantly impaired WT CRX function when the ratio of E168d2:WT 
vector reached 2:1 or higher, suggesting CRX[E168d2] actively interfered with WT CRX via an 
antimorphic mechanism, consistent with the dose-dependent toxicity observed in E168d2/+ and 
E168d2neo/+ mice.  In contrast, at the same mutant:WT vector ratios, CRX[R90W] protein did not 
disrupt WT protein function, consistent with the hypomorphic effect of R90W in mice. 
The Crx promoter is another known CRX direct target.  It contains two CRX consensus 
binding sites within a 500-bp upstream region that is required for CRX auto-activation25.  
However, unlike Rhodopsin, which is downregulated, Crx was overexpressed in E168d2 mice 
(Fig 2.2).  To determine if Crx overexpression resulted from the direct action of CRX[E168d2] 
protein on the Crx promoter, dual-luciferase reporter assays using the 0.5K Crx promoter were 
performed (Fig 2.10E).  As expected, WT CRX protein transactivated this in a concentration-
dependent manner (Fig 2.10E), while CRX[E168d2] and CRX[R90W]  at the highest concentration did 
not transactivate.  When both WT and mutant proteins were present, CRX[E168d2] interfered with 
the transactivation activity of WT CRX, even at a 1:2 mutant:WT vector ratio.  CRX[R90W] protein 
also reduced WT CRX transactivation activity, though less strongly, at the 1:1 and 2:1 
mutant:WT vector ratios.  These results suggest that both CRX[E168d2] and CRX[R90W] proteins 1) 
are less effective than WT CRX at activating target promoters, and 2) interfere with WT CRX 
autoactivation.   
Chapter II 
 
38 
 
Taken together, functional analyses of CRX[E168d2] and CRX[R90W] proteins revealed that 
they affected target gene transcription via distinct mechanisms.  While CRX[E168d2] bind DNA 
equally well as WT CRX, it fails to activate transcription and interferes with WT CRX function, 
resulting in a dose-dependent antimorphic effect.  In contrast, CRX[R90W] has reduced ability to 
bind target DNA, qualifying CRX[R90W] as a hypomorphic protein.               
 
Discussion 
E168d2 and R90W mouse lines accurately model the corresponding human diseases   
E168d2 mice model dominant ‘LCA’ or severe early-onset ‘CoRD’    
 While all homozygous K-IN mice assessed in this paper demonstrated ‘LCA’-like 
phenotypes, only E168d2/+ mice presented with dominantly inherited retinopathy characteristic 
of ‘LCA’ or severe early-onset ‘CoRD’.  Rods and cones of E168d2/+ mice were strongly 
functionally impaired from 1mo, exhibited abnormal nuclear and OS morphology and 
degenerated rapidly within the first 6mo of life (Summarized in Table 2.3).  Importantly, the cone 
deficits were more severe and occurred earlier than rod deficits.  Cone nuclei were mislocalized 
to the inner ONL at P14 and 1mo (Fig 2.7E&F) and the number of cones was decreased (32.3% 
of WT) in E168d2/+ mice at 1mo (Fig 2.8B).  In addition, the cone opsin gradient18 was highly 
disrupted in E168d2/+ and E168d2neo/+ mice (Fig 2.8M-P).  Misregulation of this gradient could 
arise either from inability of mutant CRX proteins to properly interact with co-factors to 
cooperatively regulate opsin expression, or as a result of impaired cone subtype specification.  
While these data suggest terminal differentiation of cones in E168d2/+ retina may have been 
compromised, it is unclear if cone deficits were due to impaired cell fate specification, survival, 
or both.  The accurate quantification of cone number was not possible in E168d2/+ retina at P14 
or earlier due to reduced expression of cone markers including cone opsins.  Future 
experiments tracing the cone lineage in developing E168d2/+ retinas are needed to distinguish 
these possibilities.   
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In summary, the E168d2/+ mouse phenotype closely matched the clinical features of 
patients diagnosed with LCA who carry the E168d2 mutation.  These patients showed severe 
vision loss detectable within the first few months of life, including markedly reduced ERG 
responses28–30.  Several pieces of evidence suggest that the E168d2/+ mouse also models 
human disease associated with other mutations within the class of frameshift truncation 
mutations.  First, several other frameshift and deletion mutations in human CRX caused similar 
clinical phenotypes11–13,29,31–41.  Second, in vitro functional analyses showed that these 
mutations resulted in defects in target gene transactivation similar to those we see with 
E168d223,42.  Third, the recently-identified feline model Rdy, which also carries a frameshift 
truncation mutation in Crx43, has severely reduced visual function and progressive 
photoreceptor degeneration that closely matches the E168d2/+ phenotype21,44–46.  Rdy cats 
carry a spontaneous single base-pair deletion n.546delC producing a truncated CRX protein just 
14 amino acids longer than the CRX[E168d2] protein43.  Thus, a common pathogenic mechanism is 
likely responsible for these similar phenotypes in different mammalian species, for which the 
E168d2 mouse serves as an appropriate small-animal model.   
 
E168d2neo reveals that expression levels of mutant CRX correlate with disease severity 
CRX-associated dominant diseases vary in age of onset and severity, even with similar 
mutations11,12.  The factors responsible for these phenotype variations have not yet been 
identified, but comparing findings from E168d2 and E168d2neo mice revealed one possible 
mechanism. The E168d2neo mouse, which had reduced expression of CRX[E168d2], showed a 
less severe phenotype than E168d2, resembling later-onset dominant ‘CoRD’.   
Characterization of the low expression subline E168d2neo/+ (which expressed 30% less mutant 
protein) in parallel with E168d2/+ revealed that mutant allele expression level significantly 
impacted phenotype severity.  In young E168d2neo/+ mice, the rod phenotype was almost fully 
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rescued and the cone phenotype was significantly improved by all measures performed, 
including rod and cone morphology (Figs 2.5-8), function (Fig 2.9, Table 2.2), survival (Fig 2.4).  
While older E168d2neo/+ mice did show impaired cone function and degeneration, disease 
progression was much slower compared to E168d2/+.  Thus, while the E168d2 mouse 
represented the most accurate disease model for the human CRXE168d2 phenotype, the 
E168d2neo/+ mouse modeled less severe forms of ‘CoRD’.  The expression level-dependent 
phenotypes of the E168d2 mouse lines have several implications: 1) These findings support an 
antimorphic activity for CRX[E168d2] protein; 2) In human patients carrying similar CRX mutations, 
features intrinsic to the mutation allele and/or genetic background may affect CRX expression, 
which could impact disease severity; 3) Consequently, therapy directed at shifting the ratio of 
WT to mutant CRX protein might be effective at improving vision in patients.   
 
Overexpression of CRX[E168d2] protein in E168d2 mice is caused by unknown mechanism 
 E168d2 mice overexpressed both Crx mRNA and protein in an allele specific manner 
(Fig 2.2H-J), indicating Crx misregulation occurred at the RNA level, either in the synthesis or 
degradation of the mRNA transcript.  Transient transfection assays (Fig 2.10E) showed that 
while WT CRX was able to transactivate its own promoter, CRX[E168d2] had lost transactivation 
activity and interfered with WT CRX autoregulation.  Thus, overexpression of the E168d2 allele 
in vivo was unlikely due to the direct action of CRX[E168d2] protein on the Crx promoter.  Other 
possible mechanisms for E168d2 allele-specific overexpression in vivo include suppression of a 
negative feedback regulation, changes in transcription efficiency of the E168d2 allele, or stability 
of the E168d2 transcript.  Expression of a known regulator of Crx expression, Otx2 (Accession: 
NM_144841.3), was altered in E168d2 mice.  Otx2 is required for induction of Crx expression 
during development2,47 but is normally turned off in differentiated photoreceptors when CRX 
expression reaches high levels.  Otx2 was upregulated at P21 in E168d2/+ retinas (see Tables 
3.3 & 3.4 in Chapter III), suggesting that the feedback network was affected in the mutants.  A 
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more comprehensive investigation of the network regulating Crx's transcription is required.  
Alternatively, since the level of RNA made by the mutant allele was much higher than that of the 
WT allele in E168d2/+ retinas, it is plausible that changes in Crx E168d2 mRNA stability may be 
involved.  More importantly, since this mutant allele-specific overexpression was shared by 
anther frameshift mutation, I138fs48 in Drosophila42,48, the underlying molecular mechanism could 
be conserved for this type of CRX mutation. 
 
R90W mice model mild late-onset dominant ‘CoRD’ 
 While homozygous R90W mice displayed a ‘LCA-like’ phenotype, heterozygous R90W/+ 
mice didn't exhibit changes in photoreceptor morphology or degeneration at the early ages 
tested (Table 2.3).  However, minor changes in cone function were detectable at 6mo (Fig 2.9L), 
suggesting R90W/+ has a mild dominant phenotype.  The R90W/+ phenotype closely 
resembled the clinical features of a pedigree where the equivalent human R90W mutation was 
identified10: A proband homozygous for R90W had almost complete loss of vision and was 
diagnosed with autosomal recessive LCA.  Her parents, each of whom carried one R90W allele, 
had mild cone functional defects and reduced color discrimination ability by middle age (40’s).  It 
is unknown if the cone functional defects reported for the human carriers are related to 
misregulation of cone gene expression or cone degeneration.  Several other substitution 
mutations were similarly associated with mild late-onset dominant disease in humans9–13,37,42.  
Overall, reduced numbers of rods or cones were not observed in R90W/+ mice up to one year 
of age, but disease may appear at later ages.  The mild dominant phenotype of R90W/+, not 
observed in +/- mice, as well as the CRX promoter-driven luciferase assay results (Fig 2.10E) 
suggest CRX[R90W] possesses some minor disruptive effects on WT CRX function.  Overall, 
however, unlike E168d2 and E168d2neo, there were no major phenotypic differences observed 
between R90W and R90Wneo, consistent with CRX[R90W] being predominantly a hypomorphic 
protein.  It is unknown how genetic background or environmental interactions contribute to the 
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substitution mutation disease phenotype.  The R90W mouse line provides a valid small animal 
model for investigating this subset of milder CRX-related diseases. 
 
CRX[E168d2] and CRX[R90W] protein cause disease through distinct mechanisms 
 Several pieces of evidence support that CRX[E168d2] and CRX[R90W] protein cause disease 
via different mechanisms, as illustrated in Fig 2.11.  CRX[E168d2] protein bound to DNA and 
interfered with the function of CRX WT, classifying it as an antimorphic protein with dominant-
negative activity (Fig 2.11B).  CRX[E168d2] bound target gene DNA in vivo, suggesting that the 
abnormal photoreceptor morphology and function could stem from the direct activity of 
CRX[E168d2]  on target gene expression.  The antimorphic effect of CRX[E168d2] is unlikely to 
involve interference with NRL function, since CRX[E168d2] did not interfere with NRL 
transactivation (Fig 2.10D) and a similar truncation mutation in bovine CRX C160 (1-160) 
maintained interaction with NRL24.  The E168d2 mouse model thus demonstrates the effects of 
an antimorphic truncated CRX protein associated with human disease. 
 The CRX[R90W] protein had reduced DNA binding and weakly promoted transcription in 
vitro, classifying CRX[R90W] as a hypomorphic protein (Fig 2.11C, F).  Although binding of 
CRX[R90W] to the BAT-1 oligo in vitro was reduced (Fig 2.10A), CRX[R90W] associated with CRX 
target DNA in vivo (Fig 2.10C), suggesting co-factors may anchor CRX[R90W] to target DNA.  
CRX[R90W] weakly promoted NRL-mediated transactivation of the Rho promoter in vitro (Fig 
2.10D), consistent with early findings that CRX[R90W] protein reduced the physical interaction with 
NRL24.  Thus, even though CRX[R90W] was associated with target promoters in vivo, it may have 
lost specific interactions with co-factors, therefore reducing its function.  In Drosophila, human 
R90W was able to partially rescue the otduvi phenotype, consistent with a hypomorphic 
mechanism48.  Taken together, our results show that CRX[R90W] is a predominantly hypomorphic 
mutant CRX protein, representative of substitution mutations associated with mild forms of CRX 
disease.         
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Mechanistically distinct mutations underlie CRX-associated disease 
 The molecular functions of several CRX mutations associated with human retinopathy 
have been investigated in vitro10,23,42 and in vivo in Drosophila48.  Such studies indicate that 
mutant CRX proteins have distinct molecular functions, which could in part explain the variation 
in CRX-disease phenotypes.  The distinct phenotypes of mice carrying E168d2, an antimorphic 
frameshift mutation, and R90W, a hypomorphic substitution mutation, further expand our 
understanding of the impact of mutation type on disease pathology and closely match the 
functions and associated phenotypes of other similar type mutations.  This suggests that 
E168d2 and R90W K-IN mice are representative animal models for two larger groups of disease 
causing mutations, increasing their utility as research tools for studying pathology and 
developing therapies.  There are likely additional mechanisms of CRX-associated disease yet to 
be modeled in vivo, such as substitution mutations that do not affect DNA-binding but are 
nonetheless associated with dominant disease10,23,42.  Collectively, these studies demonstrate 
the diversity of molecular defects mediating CRX-associated disease and highlight the value of 
having multiple small-animal models to understand them. 
 
For detailed Materials and Methods see Appendix B 
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Tables 
 
 
Table 2.1) PCR Primer Pairs for Genotyping, qRT-PCR and qChIP.  List of oligonucleotides 
used for all PCR-based analyses. 
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Table 2.2) Percent reduction* of ERG peak amplitudes in E168d2/+ and E168d2neo/+ mice 
 
Dark-adapted A-waves     
Average: -0.02, 0.387,  
0.875  Cds/m2 flashes 
Dark-adapted B-waves   
Average: -0.02, 0.387,  
0.875 Cds/m2 flashes 
Light-adapted B-waves                    
Average: 0.40, 0.88, 1.38, 
1.88, 2.39, 2.82 Cds/m2 
flashes 
Age E168d2/+ E168d2neo/+ E168d2/+ E168d2neo/+ E168d2/+ E168d2neo/+ 
1mo 73.3 ±5.3 25.9 ±1.1 68.2 ±1.6 25.6 ±5.3 72.8 ±10.2  41.3 ±7.3  
3mo 76.4 ±5.1 25.2 ±1.2  73.1 ± 2.8  26.3 ±1.8  82.4 ±4.3 46.7 ±6.3 
6mo 82.6 ±8.7  21.8 ±4.5 76.3 ±0.3 17.3 ±1.9 78.9 ±12.9 41.4 ±5.3 
 
*Average percent reductions were calculated based on Fig 7 data.  ±STDEV     
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Table 2.3) Summary of retinal phenotypes of Crx E168d2, R90W and KO mice 
 
Function 
(ERG) 
OS 
Length 
Nuclear 
position 
Opsin 
Gradient 
Photoreceptor 
degeneration 
timecourse 
Gene 
expression 
Disease 
model 
Genotype Rod  Cone Rod Cone Cone Rod Cone P10 P21 
 
WT ++++ ++++ ++ OONL +++ - - +++ +++ 
E168d2/+ + + + MONL - 1-6mo 1mo + + LCA 
E168d2neo/+ +++ ++ ++ IONL + - 1mo-1yr + ++ CoRD 
R90W/+ ++++ ++++ ++ OONL ++ - - ++ +++ 
Mild 
CoRD 
+/- ++++ ++++ ++ OONL ND* - - ++ +++ 
E168d2/d2 - - - - - 1-3mo 1-3mo - - LCA 
R90W/W - - - - - 1-3mo 1-3mo - - LCA 
-/- - - - - - 1-3mo 1-3mo - - LCA 
 
‘+’ qualitative graded levels; ‘-‘ null; *ND: Not determined  
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Figure 2.1) Generation of mechanistically distinct Knock-IN (K-IN) mouse lines for CRX-
associated disease: E168d2, E168d2neo, R90W and R90Wneo.  A) Diagram of mouse Crx 
locus showing gene structure and strategy for generating Crx E168d2 and R90W K-IN lines.  
E168d2neo and R90Wneo each carry the indicated targeting construct containing loxP-flanked 
Neo cassette in Intron 3-4 as a selection marker.  The final E168d2 and R90W lines were 
generated from the respective ‘Neo+’ sublines by Sox2-Cre-mediated excision in germline.  B) 
Germline transmission of K-IN constructs was confirmed by Sanger sequencing of genomic 
DNA from homozygous E168d2/d2, R90W/W and WT mice and aligned to genomic mCrx.  
Shaded ‘∙‘ in the grey boxes indicate fully conserved sequences, unshaded ‘∙‘ denote deletions, 
and letters indicate base pair substitutions.  Gene position (above alignment), consensus 
sequence (below alignment) and translated amino acid sequence are shown.  Amino acid 
changes in E168d2 and R90W are shown in red text with ‘*’ indicating the novel stop codon in 
E168d2.  Further generations of E168d2 and R90W mice were genotyped by allele specific 
PCR amplification of genomic DNA (Table 2.1). 
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Figure 2.2) Differential expression of mutant CRX protein/RNA in K-IN mouse retinas.  A-
G) Paraffin embedded sagittal sections of P10 mouse retinas were stained with the mouse        
monoclonal CRX M02 antibody (Abnova) and imaged by fluorescent microscopy.  Scale bars: 
25μM. H) SDS-PAGE and Western blot analyses of CRX proteins made by the indicated mouse 
strains at P10 using the rabbit polyclonal CRX 119b-1 antibody and mouse monoclonal anti-β-
ACTIN (α-BACT, Sigma-Aldrich).  Positive bands correlating with the ~37kD full-length CRX and 
~27kD truncated CRX[E168d2] are visible.  Lanes are numbered for reference (below).  I) CRX 
protein levels were quantified by measuring the intensities of the CRX[E168d2] and full-length 
bands normalized to the β -ACTIN control using LI-COR Odyssey Image Studio software.  The 
results are presented as fold changes (FC) relative to full-length CRX level in WT retina.  
(*p≤0.05)  J) Crx mRNA levels were determined by quantitative real-time PCR using allele 
specific PCR primer pairs.  Separate primer pairs were used to amplify WT Crx alone and total 
Crx (WT+mutant) in E168d2 and R90W mice (see materials and methods). The results are 
presented as FC relative to WT retina. (*p≤0.05) 
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Figure 2.3) Homozygous E168d2/d2 and R90W/W mice develop ‘LCA’-like retinopathy.  A-
L) H&E staining of paraffin embedded sagittal retinal sections for E168d2/d2, R90W/W and -/- 
mice at P14, 1mo and 3mo and imaged by light microscopy, showing the lack of photoreceptor 
outer segments (OS) and loss of ONL cells with age.  Scale bars: 100μM.  M-O) Reduction of 
ONL thickness in mutant retina at each age was quantified using ‘spider graph’ morphometry.  
Significant differences in overall ONL thickness were determined by testing genotype*distance 
interactions (by two-way ANOVA) at 1mo (p=0.002) and 3mo (p=0.0001), followed by individual 
comparisons to WT: *p<0.05.  INF-inferior retina, SUP-superior retina. 
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Figure 2.4)  Detection of programmed cell death in E168d2, R90W and -/- mice.  A-O) Cells 
undergoing programmed cell death were detected by fluorescent TUNEL staining of paraffin 
embedded sagittal sections.  WT, E168d2/d2, R90W/W and -/- retinas were assessed at P21 
(A-D) and P35 (F-I).  TUNEL+ cells (white arrows) in the ONL of WT, E168d2/d2, R90W/W and 
-/- retinas were quantified at P21 (E) and P35 (J).  K-N) WT, E168d2/+, E168d2neo/+, and 
R90W/+ retinas were assessed at P35.  O) Quantification of TUNEL+ cells in P35 WT, 
E168d2/+, E168d2neo/+, and R90W/+ retinas confirms increased programmed cell death in 
E168d2/+ retinas. Scale bar: 25µM.  (*p<0.05; Error bars: STDEV)  
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Figure 2.5) Heterozygous E168d2/+ mice, but not R90W/+, develop dominant retinopathy.  
A-P) Retinal morphology of the indicated heterozygous mutant mice was assessed by H&E 
staining of paraffin embedded sagittal sections at P14, 1mo, 3mo, and 6mo.  Shortened 
photoreceptor outer segments and ONL cell loss are apparent in E168d2/+ retina only.  Scale 
bars: 100μM   Q-T) ONL thickness was assessed by spider graph morphometry at the indicated 
ages.  E168d2/+ (red line) shows progressive thinning of the ONL through 6mo, while it’s low 
expression subline, E168d2neo/+ (blue line), and R90W/+ (green line) do not.  Significant 
differences in overall ONL thickness were determined by testing genotype*distance interactions 
(by two-way ANOVA).  Significant interactions were observed at P14 (p=0.03) and 6mo 
(p=0.03), followed by testing individual comparisons to WT: *p<0.05.  INF-inferior retina, SUP-
superior retina.  U-W) The ultra structure of rod outer segment (OS) and nuclear morphology 
was assessed by transmission electron microscopy.  Micrographs of rod outer segments 
proximal to RPE from WT control (U), E168d2/+ (V) and E168d2neo/+ mice (W).  E168d2/+ 
OS’s are highly disorganized showing ‘wave-like’ OS membrane stacks ‘*’, vesiculated 
membranes ‘+’ and vertically oriented OS membranes (triangles).  E168d2neo/+ OS’s only 
show minor ‘wave-like’ patterns and vesiculated membranes.         
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Figure 2.6) E168d2/+ mice have disorganized nuclear architecture.  A-F) Transmission 
electron micrographs of P21 WT, E168d2/+ and E168d2neo/+ retinas showing the ONL nuclei in 
the region proximal to inner segments (IS) (A-C) and OPL (D-F).  White arrows indicate cone 
nuclei in WT (A) and cone-like nuclei in mutant retinas (B, C, E).  E168d2/+ have many ONL 
nuclei with decondensed chromatin (B, E white arrows) which are either displaced cones or 
rods with disorganized nuclear architecture.  E168d2neo/+ also have several photoreceptors 
with ‘cone-like’ patterns that are mislocalized to the middle and inner ONL (C, white arrows).  
Highly electron dense nuclei (white pentagon), corresponding with pyknotic nuclei, were 
identified in the ONL of E168d2/+ (E) and E168d2neo/+ (F) samples but not in WT (D). G) 
Quantification of percentage area of nuclei consisting of condensed heterochromatin show a 
significant reduction of rod heterochromatin in E168d2/+ but not E168d2neo/+ retinas (*p<0.05; 
Error bars: SEM).  Image scale bars: 2μM.   
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Figure 2.7) Heterozygous E168d2/+, E168d2neo/+ and R90W/+ mice display abnormal 
cone nuclear localization in developing and adult retina.  A-D) Sagittal retinal sections of 
the indicated mice at 1mo, stained for cone arrestin (CARR) (green) and nuclear marker DAPI 
(blue).  To assess cone nuclear location, the ONL was arbitrarily divided into three zones, outer 
ONL (OONL), mid ONL (MONL) and inner ONL (IONL).  A) WT cone nuclei were found only in 
the OONL, while E168d2/+, E168d2neo/+ and R90W/+ had varying numbers of cones localized 
to IONL or MONL (B&C white arrows).  E, F) Cone nuclear position was quantified by counting 
the fraction of CARR+ nuclei in each ONL zone of sagittal retinal sections from P14 or 1MO 
mice of the indicated genotype (*p<0.05). 
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Figure 2.8) Heterozygous E168d2/+, E168d2neo/+ and R90W/+ mice display distinct 
changes in cone density and M/S opsin gradient formation.  A) Diagram of selected regions 
of flat-mounted retina for cone density image analyses. B-D) Cone density of 1mo and 1yr old 
mice was determined by counting PNA+ cells on flat-mounted retinas in the dorsal (D), central 
(C), nasal/temporal (N/T) and ventral (V) regions.  Genotype*retinal region interaction (by two-
way ANOVA) was significant at 1mo (p=0.04) but not 1yr (p=0.11), therefore differences in 
PNA+ cells in each region were tested at 1mo but not 1yr.  B) Total cone density over all 
regions (*p<0.05).  C-D) Cone density in each region in 1mo and 1yr old mice (*p<0.05).  E-L) 
Flat-mounted retinas from 1mo mice of the indicated genotype were stained for OPN1SW (SOP, 
green), red/green opsin (MOP, red) and the pan cone marker peanut agglutinin (PNA, blue), 
showing sample images from the dorsal (E-H) and ventral (I-L) regions.  Image scale bars: 
25μM.  Unlike WT samples (E&I), E168d2/+, (F&J) and E168d2neo/+ (G&K) samples show a 
small number of PNA+ cones that did not express either cone opsin (white arrows).  M-P) 
Fraction of cones in each region expressing SOP, MOP, both SOP/MOP or no opsin (*p<0.05).  
Error bars: SEM 
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Figure 2.9) Graded changes in retinal function in E168d2 and R90W mice.  A-C) Retinal 
function of 1mo homozygous E168d2/d2 and R90W/W mice was assessed by 
electroretinography.  D-L) Retinal function of E168d2/+, E168d2neo/+ and R90W/+ and +/- mice 
was assessed by electroretinography at 1mo (D-F), 3mo (G-I) and 6mo (J-L).  Averaged peak 
amplitude responses for dark-adapted A-waves and B-waves and light-adapted B-waves are 
plotted against the log of the flash intensity (Log [cd*s/m2]).  Genotype*flash intensity 
interactions for peak amplitude (by two-way ANOVA), were significant (p<0.05) at all ages for 
each wave form tested.  E168d2/+ mice show severe deficits in all wave responses at each age 
compared to responses from either WT or E168d2neo/+ mice (green vs. black and red line, 
respectively).  Peak responses in E168d2neo/+ mice are higher than E168d2/+ (red vs. green 
line), but remain significantly decreased compared to WT (red vs. black line) with exceptions for 
6mo dark-adapted B-waves (K).  R90W/+ and +/- mice have mostly normal retinal function (blue 
or orange vs. black line) but R90W/+ have subtle significant deficits in light-adapted B-waves at 
6mo (L, blue vs. black line).  (Relative to WT: *p<0.05; relative to E168d2neo/+: *‘p<0.05, 
brackets indicate all enclosed data points are significant).  Error bars: SEM. 
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Figure 2.10) CRX[E168d2] and CRX[R90W] affect target gene transcription through distinct 
molecular mechanisms.  A) Electrophoresis mobility shift assays (EMSA) to measure the DNA 
binding activity of HEK293-expressed CRX[E168d2] and CRX[R90W] protein to the Rho BAT-1 motif.  
CRX mammalian expression vectors pCAGIG-CRX WT, E168d2 or R90W and their negative 
control vector pCAG-Gfp (-) were individually transfected into HEK293 cells.  A 2-fold dilution 
series of nuclear protein extract made from each transfection were incubated with 700IRdye-
labeled DNA probes, either BAT-1 or mutated BAT-1 lacking CRX-binding sites (BAT-1 Mut AB) 
(sequence below EMSA).  The resulting protein/DNA complexes were resolved on 5% non-
denaturing PAGE gel and imaged on the LI-COR Odyssey system.  Novel bands corresponding 
to protein/DNA complexes from full-length CRXs (FULL, either WT or LF), truncated CRX 
(E168d2) and non-specific (N.S.) protein(s), as well as free probe (F.P.) are indicated.  B) 
Western blot for the amount of CRX protein (antibody 119b-1) present in each nuclear extract.  
To compare binding activity, CRX protein levels from different nuclear extracts were normalized 
and equal ratios were used for EMSA reactions.  C) Quantitative chromatin immunoprecipitation 
assays for promoter occupancy of CRX in P14 WT and E168d2/d2, R90W/W and -/- mutant 
retinas.  The indicated target gene promoters were used in qPCR assays on CRX-
immunoprecipitated chromatin and the results are presented as enrichment of CRX over IgG 
control.  Like WT protein, both CRX[E168d2] and CRX[R90W] are enriched on the promoters 
analyzed.  D-E) Dual-luciferase assays showing combined transactivation activity of NRL, CRX, 
CRX[E168d2] and CRX[R90W] in transfected HEK293 cells on two promoter-luciferase reporters, 
Rhodopsin (BR-130) (D) and Crx (0.5K mouse Crx) (E). Comparing to pcDNA3.1hisc control, for 
BR-130: all test plasmid combinations were significantly different; for 0.5K Crx: only pCAG-
E168d2 and pCAG-R90W were not significantly different.  Significant differences of post hoc 
comparisons are indicated by bracketed ‘*’ (FDR p<0.09; comparisons were made to the left 
most bracket; Error bars: STDEV). 
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Figure 2.11) Models for CRX[E168d2] and CRX[R90W] mechanisms of pathogenesis in K-IN 
mice.  A) In WT mice, CRX binds to DNA, recruits and synergizes with co-factors including NRL 
and chromatin modulators to promote target gene transcription.  B) In E168d2/+ mice, the 
antimorphic CRX[E168d2] protein directly competes with CRX WT to act on target gene promoters.  
Since CRX[E168d2] protein is overexpressed compared to WT, its antimorphic effect is amplified 
and results in severe reductions in target gene transcription and retinopathy resembling LCA.  
C) In R90W/+ mice, CRX[R90W] protein does not impair the function of CRX WT and transcription 
in adult mice is largely normal.  R90W/+ mice have only a mild retinal phenotype similar to a 
late-onset CoRD.  D) In -/- mice, the loss of CRX leads to the failure to recruit co-factors to 
target gene promoters and expression is silenced.  E) In E168d2/d2 mice, CRX[E168d2] protein 
binds to the promoters of target genes, which interferes with the activity of other transcription 
factors, resulting early-onset LCA with a faster course of retinal degeneration than -/-.  F) In 
R90W/W mice, CRX[R90W] protein was found to still associate with target gene promoters despite 
having reduced DNA binding in vitro.  However, this confers only modest gains in target gene 
transcription over -/- and does not establish normal retinal function.  Thus, CRX[R90W] protein is a 
functionally impaired protein but retains some residual transactivation activity.  R90W/W mice 
most closely model LCA.      
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Introduction- Assessment of retinal gene expression in E168d2 and R90W mouse 
models 
 Given CRX's critical role in photoreceptor development and gene expression, I 
hypothesized that the distinct phenotypes observed in the E168d2 and R90W mouse 
models were directly related to unique abnormalities in photoreceptor gene expression.  
Previous studies have shown that retinal function and morphology are directly related to 
photoreceptor gene expression and can be greatly affected by disruptions in the retinal 
transcription factor network1–6.  Our goal was to correlate the E168d2 and R90W 
phenotypes with their specific retinal gene expression profiles.  We assessed whole-
genome mRNA expression in P10 heterozygous and homozygous and P21 
heterozygous E168d2 and R90W mice using expression microarrays and RNA-Seq 
technologies.  We validated several expression changes using immunofluorescent 
histochemistry and qRT-PCR.  Given CRX's widespread function in photoreceptor gene 
expression, phenotypic differences could stem from different types of expression 
abnormalities.  We sought to determine if disease type and severity was affected by 
changes in different sets of genes or by graded changes in a common set of genes.  
Assessing the commonalities and differences in gene expression will aid to our 
understanding of what genes and cellular pathways underlie the distinct pathologies of 
these mouse models. 
 In addition, we correlated expression differences with the DNA binding of CRX 
and the rod-specific transcriptional co-regulator NRL in photoreceptors.  Previous 
studies identified a strong correlation with genomic CRX7 and NRL8 DNA-binding and 
gene expression.  Investigating whether this correlation is maintained in E168d2 and 
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R90W mice was thought to be especially critical to determine whether or not mutant 
CRX proteins were primarily affecting direct target genes of WT CRX.             
 
Results 
3.1. Gene expression in P10 homozygous Knock-IN mice 
3.1.i) Microarray analysis of gene expression changes in homozygous mutants 
We first compared retinal transcription profiles of homozygous E168d2neo and 
R90Wneo mice with WT and -/- controls using Illumina gene expression microarrays to 
determine the effects of mutant CRX protein on retinal gene expression.  We chose to use 
homozygous mice from the Neo+ sublines, which express the mutant protein at lower levels 
than the final lines, for the gene profiling analyses to avoid alterations in gene expression that 
could arise strictly from mutant CRX overexpression.  Unlike subline differences observed in 
heterozygous mutant mice, morphological and functional characterization demonstrated that the 
phenotypes of homozygous mice from neo+ and final neo- sublines were indistinguishable.  
Expression profiling results were validated by qRT-PCR for several genes in all sublines.  RNA 
from sex-matched pairs of P10 retinas for each genotype was reverse transcribed into cDNA, 
which was hybridized onto Illumina mouse Ref6 expression microarrays.  Microarray analyses 
showed a high degree of overlap of differentially expressed genes in homozygous E168d2neo, 
R90Wneo and -/- mice (Fig 3.1A&B).  The complete list of differentially expressed genes is 
available in Tables S2 & S3 (Tran NM et al. PLOS Genetics 2013), and the raw datasets are 
available at NCBI GEO website (http://www.ncbi.nlm.nih.gov/gds, access number: GSE51184).  
For downregulated genes: 70.6% of E168d2neo and 93.5% of R90Wneo genes were shared 
with -/- (Fig 3.1A).  For upregulated genes: 59.8% of E168d2neo and 75% of R90Wneo genes 
were shared with -/- (Fig 3.1B).  
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 While E168d2neo, R90Wneo and -/- mutations affected similar sets of genes, distinct 
degrees of gene expression changes were observed.  Heat map analysis showed the majority 
of shared downregulated genes were more strongly reduced in E168d2neo and -/- compared to 
R90Wneo (Fig 3.1D).  The less reduced expression of downregulated CRX target genes in 
R90Wneo mice suggests that R90Wneo retains some weak ability to promote transcription.  
E168d2neo and -/- had similar heat map profiles but several key photoreceptor genes were 
lower in E168d2neo including: Rho, Arr3, Ramp3, Drd4, Cpm, and Pde6c (Accessions: 
NM_145383.1, NM_133205.3, NM_019511.3, NM_007878.2, NM_027468.1, AF411063.1, 
respectively).  The more severe reduction in gene expression in E168d2 is consistent with its 
accelerated photoreceptor degeneration compared to R90W and -/-.  It is notable that many 
shared downregulated genes encode proteins in the phototransduction and visual cycle 
pathways essential for establishing vision (Fig 3.1E), including: Opn1sw, Opn1mw, Gnat1, 
Gnat2, Rcvrn, Pde6a, Pde6g, (Accessions: NM_007538.3, NM_008106.2, NM_008140.2, 
NM_008141.2, NM_009038.2, NM_146086.2, NM_012065.2, respectively) Rho, Arr3, and 
Pde6c.  Other downregulated genes encode proteins with function in key cellular processes, 
including metabolism and mitochondrial function, membrane stability/function, synaptic function, 
intercellular transport, and transcription/translation (Fig 3.1E), which likely contribute to the 
morphological and functional defects.  Furthermore, many downregulated genes were 
associated with the human diseases RP, LCA and CoRD (Table 3.1, https://sph.uth.edu/retnet/), 
overlapping with those reported for CRX mutations. 
 
3.1.ii) RNA-Seq analysis of gene expression changes in homozygous mutants 
 In addition assessing retinal gene expression using microarrays, we performed Next-
generation RNA sequencing (RNA-Seq).  Next-generation sequencing provides unbiased 
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quantitative measurements of an RNA population.  It has been shown to yield more robust 
measures of gene expression allowing for greater resolution of genes expressed at low levels 
and small differences in expression.  RNA-Seq has effectively been used in the Nrl KO mouse 
to identify additional changes in gene expression, when compared to microarray1,3,8–10.  Taking 
these findings into account, we decided to further characterize the retinal gene expression of 
P10 homozygous E168d2 and R90W mice using RNA-Seq.   
 The mRNA from sex-matched pairs of P10 WT and homozygous E168d2 and R90W 
mouse retinas was sequenced using the Illumina HiSeq platform.  Unlike microarray 
experiments, E168d2 and R90W Neo- mice were used since these mice most closely model 
human disease.  Sequencing reads were aligned to the genome and the raw number of reads in 
counts per million (CPM) per gene were determined (Table 3.2).  Genes with a minimum read 
count of ≥5 CPM in at least one genotype were analyzed for differential expression compared to 
WT.  In E168d2/d2 retinas 673 genes were found to be differentially expressed by more than 2-
fold (425 downregulated, 248 upregulated)(FDR < 0.05).  In R90W/W mice 264 genes were 
differentially expressed (196 downregulated, 70 upregulated) by the same criteria.  For both 
genotypes, more differentially expressed genes were detected by the RNA-Seq method than by 
microarray and a high degree of overlap was observed between the datasets, particularly in 
downregulated genes (Fig 3.2A-F).  In E168d2/d2, 139 downregulated genes are shared 
between microarray (56%, 139/250) and RNA-Seq (35%, 139/396) platforms, while a lower 
percentage of upregulated genes are shared between microarray (39%, 37/96) and RNA-Seq 
(15%, 37/248) (Fig 3.2A-B).  In R90W/W, 46 downregulated genes are shared between 
microarray (61%, 46/76) and RNA-Seq (23%, 46/196) platforms (Fig 3.2A-B), while a lower 
percentage of upregulated genes are shared between microarray (54%, 6/11) and RNA-Seq 
(9%, 6/70) (Fig 3.2C-D).  The improved sensitivity of the RNA-Seq platform is demonstrated by 
the detection of genes not detected in microarray like Opn1sw, a gene expressed in cones 
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which comprise only 3% of retinal cells.  Differentially expressed genes in E168d2 and R90W 
RNA-Seq data share even more genes than their genotype-matched microarrays (168 
downregulated, 48 upregulated) (Fig 3.2E-F), indicating platform-specific differences in gene 
expression profiles.  Overall, RNA-Seq results in homozygous mice match well with microarray 
results and provide a more robust profile of retinal gene expression in E168d2 and R90W mice.   
 We analyzed the expression profiles of homozygous E168d2 and R90W retinas with 
particular focus on the expression of known rod and cone genes.  Volcano plots of expression 
fold-change compared to WT show that E168d2/d2 and R90W/W have a general trend favoring 
downregulation of expression (Fig 3.3A-B).  We tracked the expression of 12 genes with known 
function in photoreceptors (labeled in white, Fig 3.3A-C): genes involved in rod 
phototransduction (Rho, Gnαt1, Grk1, Rcvrn), cone phototransduction (Arr3, Pde6h, Opn1sw, 
Opn1mw), transcription in rods (Esrrβ, Nrl, Nr2e3), transcription in cones (Rxrγ) or transcription 
in rods/cones (Crx, Otx2).  E168d2/d2 and R90W/W mice exhibit significantly reduced 
expression of rod and cone genes involved in phototransduction, a slight reduction in the 
expression of Nrl, while Rxrγ was found to be highly overexpressed (Fig 3.3A-B).  A scatter plot 
comparing fold-changes in E168d2/d2 and R90W/W, shows that many genes including several 
involved in phototransduction (Arr3, Pde6h, Rho and Grk1) are more strongly downregulated in 
E168d2/d2 than R90W/W (Fig 3.3C), corresponding with microarray results.  These results 
suggest that both E168d2/d2 and R90W/W have reduced expression of photoreceptor genes 
and that expression is more strongly impaired in E168d2/d2 than R90W/W.   
 
3.1.iii) Validation of microarray and RNA-Seq results for homozygous mice 
         To confirm graded changes in target gene expression, levels of several key CRX target 
genes were validated in homozygous mice of all mutant lines using IF staining (Fig 3.3D-G) 
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and/or qRT-PCR analyses (Fig 3.3 H-K, Table 3.1, Table 3.3).  IF staining showed that 
homozygous E168d2neo retinas failed to produce rhodopsin (RHO) in contrast to -/-, which still 
made a low amount of RHO (Fig 3.3 E vs. G).  This suggests that CRX[E168d2] protein has an 
inhibitory effect on Rho expression beyond complete loss of CRX protein.  Homozygous 
R90Wneo retinas, on the other hand, produced RHO at a level higher than -/- but much lower 
than WT retinas (Fig 3.3 F vs. G & D).  Expression changes of a number of genes in the retinas 
of homozygous mutants from the neo+ and final neo- lines were validated using qRT-PCR, 
including the rod gene Rho and the cone genes Arr3, Opn1sw and Opn1mw (Fig 3.3 H-K, Table 
3.3).  The results, presented as fold change (FC) relative to WT, from P10 homozygous mice of 
the ‘low expression’ subline and final line of each mutation were compared (Fig 3.3H-K).  Rho 
expression was essentially abolished in both E168d2 and E168d2neo mice.  In contrast, R90W 
and R90Wneo mice expressed Rho at levels slightly higher than -/- (Fig 3.3H).  These results 
are consistent with the microarray and IF results described above.  Expression of the cone gene 
Arr3 was not detectable in E168d2 or E168d2neo mice, while residual amounts were detected 
in R90W, R90Wneo and -/- mice (Fig 3.3I).  Opn1sw and Opn1mw were strongly downregulated 
in homozygous mice of all models.  The loss of expression of genes involved in rod/cone 
phototransduction explains the loss of visual function in these mice.  Together, our results 
suggest that the E168d2 mutation produced a direct antimorphic effect on photoreceptor gene 
expression beyond CRX deficiency, while R90W is a hypomorph mutation, resulting in a CRX 
protein with impaired residual transcriptional regulatory function.   
 
3.2) Gene expression in P10 and P21 heterozygous Knock-IN mice 
3.2.i) RNA-Seq analysis of gene expression changes in heterozygous mutants 
 Since CRX-associated retinopathies are typically inherited in a dominant fashion, the 
gene expression profiles of heterozygous E168d2 and R90W mouse retinas were assessed to 
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determine potential disease pathways contributing to the phenotypes of each model.  mRNA 
from sex-matched retinas of E168d2/+, E168d2neo/+ and R90W/+ mice were sequenced, 
aligned and the fold-change compared to WT was determined, as above.  Ages P10 and P21 
were selected to give both a developmental and a mature retina timepoint.  Volcano plots of P10 
fold-changes compared to WT for E168d2/+ and E168d2neo/+ show a general favoring 
downregulation, while few genes in R90W/+ were >2-fold different (Fig 3.4A-C).  Tracking of the 
same set of known photoreceptor genes as in homozygous analysis reveals that rod and cone 
phototransduction genes (Pde6h, Rho, Rcvrn, Gnαt1, Arr3, Opn1sw, Opn1mw) are 
downregulated in both E168d2/+ and E168d2neo/+.  Rxrγ was found to be upregulated in 
E168d2/+ but not E168d2neo/+.  None of these genes were >2-fold differentially expressed in 
R90W/+.  E168d2/+ and E168d2neo/+ show a high degree of overlap in downregulated 
(E168d2/+: 52%, 71/136 and E168d2neo/+: 83%, 71/85) and upregulated (E168d2/+: 39%, 
24/61 and E168d2neo/+: 63%, 24/38) genes (Fig 3.4D-E).  The few genes that were 
differentially expressed in R90W/+ exhibited overlap with E168d2/+ (60%, 12/20 downregulated 
and 58%, 7/12 upregulated) (Fig 3.4F-G).            
 Volcano plots of P21 E168d2/+, E168d2neo/+ and R90W/+ show similar patterns to P10 
data with some notable differences (Fig 3.4H-J).  While several of the tracked phototransduction 
genes remained downregulated in E168d2/+ (Opn1sw, Pde6h, Rcvrn, Opn1mw, Rho, Arr3), 
only the cone-specific Opn1sw and Pde6h were found to be downregulated in E168d2neo/+, 
this recovery in expression of rod genes is consistent with the improvement in rod morphology 
and survival in E168d2neo/+ mouse retinas (Fig 3.4H-I).  Few genes overall and none of the 
tracked genes were differentially expressed in R90W/+ mouse retinas (Fig 3.4J).  E168d2/+ and 
E168d2neo/+ show a high degree of overlap in downregulated (E168d2/+: 46%, 69/150 and 
E168d2neo/+: 83%, 69/83) and upregulated (E168d2/+: 26%, 12/47 and E168d2neo/+: 63%, 
12/19) genes (Fig 3.4K-L).  The few downregulated genes in R90W/+ exhibited overlap with 
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E168d2/+ (81%, 22/27) while the upregulated genes exhibited little overlap (4%, 1/27) (Fig 
3.4M-N).  At both P10 and P21 more differentially expressed genes were identified in E168d2/+, 
indicating changes may either be stronger in E168d2/+ pushing them past the 2-fold cut-off or 
affected in E168d2/+ but not in E168d2neo/+ mouse retinas.  To discern between these two 
possibilities, scatter plots of the fold-change to WT of E168d2/+ vs. E168d2neo/+ or R90W/+ 
were made at P10 and P21 (Fig 3.5A-D).  In P10 E168d2/+ vs. E168d2neo/+, few genes were 
>2-fold different.  Of the tracked genes, only the cone-specific Pde6h and Arr3 were >2-fold 
different, with both being higher in E168d2neo/+ (Fig 3.5A).  Similarly to P10, few genes were 
>2-fold different in P21 E168d2/+ vs. E168d2neo/+.  Of the tracked genes, only Pde6h and the 
rod-specific Rcvrn were different with both being higher in E168d2neo/+ (Fig 3.5B).  As 
expected, in both P10 and P21E168d2/+ vs. R90W/+ several genes, including many of the 
tracked genes, were expressed >2-fold higher in R90W/+ than E168d2/+.  Overall these results 
indicate that photoreceptor transcription is highly disrupted in E168d2/+ and E168d2neo/+ but 
only subtly affected in R90W/+ correlating with the minor phenotype of R90W/+ mice.  Since few 
genes are >2-fold different between E168d2/+ and E168d2neo/+, the more severe phenotype of 
E168d2/+ is unlikely to be caused by changes in a distinct set of genes and is more likely 
related to small graded changes in the same set of changes.                
 
3.2.ii) Validation of RNA-Seq results for heterozyous mutants 
 To determine if gene expression changes in heterozygous mice followed the same trend 
as homozygous mutants, expression of the selected CRX target genes, Rho, Arr3, Opn1sw and 
Opn1mw, was evaluated in heterozygous mutants using IF staining of retinal sections at 1mo of 
age (Fig 3.5E-H) and/or qRT-PCR at P10 and P21 (Fig 3.5I-L, Tables 3.3 & 3.4).  IF staining for 
RHO at 1mo showed that E168d2/+ mice displayed low intensity of RHO staining, some of 
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which was mislocalized to the ONL (Fig 3.5 F vs. E), suggesting impaired RHO trafficking.  This 
phenotype was not seen in E168d2neo/+ and R90W/+ retinas (Fig 3.5G, H vs. E).  qRT-PCR 
analyses showed that E168d2/+ mice exhibited persistent downregulation of all genes tested in 
both P10 and P21, despite some degree of recovery at P21 (Fig 3.5I-L, Tables 3.3 & 3.4).  
Expression of these genes was also decreased in E168d2neo/+ mice, but significant 
improvements were seen for Rho and Opn1mw, compared to E168d2/+ mice.  The more severe 
impairment of gene expression in E168d2/+ compared to E168d2neo/+ demonstrates the 
dosage effect of CRX[E168d2] mutant protein.  In contrast, R90W/+ and +/- mice exhibited 
reduction in the expression of some genes at P10 but normal expression was observed at P21.  
The degree of expression changes in individual mutants varied from gene to gene.  These 
results suggest that CRX[E168d2] mutant protein actively impaired CRX target gene transcription in 
the presence of WT protein, consistent with an antimorphic mechanism.  This antimorphic effect 
depends on CRX[E168d2] protein dosage and can be reduced by decreasing CRX[E168d2]  
expression.  In contrast, R90W/+ essentially phenocopied the phenotype of +/-, suggesting that 
CRX[R90W] protein did not severely interfere with the function of WT CRX in vivo, which allowed 
for normal photoreceptor gene expression by P21. 
 
3.3. Connecting expression changes with CRX functional role in photoreceptor 
differentiation 
 In order to connect the differences in retinal gene expression observed in E168d2 and 
R90W mice with the functional role of CRX, we performed hierarchical clustering analysis on 
differentially expressed and compared expression changes with the DNA-binding patterns of 
CRX and the rod-specific co-regulator NRL.  Hierarchical clustering of differentially expressed 
genes among P10 E168d2/+, E168d2neo/+, R90W/+, E168d2/d2, R90W/W and P21 E168d2/+, 
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E168d2neo/+ and R90W/+ reveals groups of genes that exhibit distinct patterns of expression 
(Fig 3.6, 3.7).  We compared trends in expression in Nrl KO, the DNA-binding of CRX in WT and 
Nrl KO retinas and the DNA-binding of NRL in WT retinas and performed G-profiler pathway 
analysis on each of these groups.   
 Here we highlight two of the designated groups which show the most dramatic changes 
in gene expression.  Group 1 (Fig 3.6) is composed of genes that are primarily downregulated 
across genotypes.  Expression of genes within this group is noticeably lower in P10 E168d2/d2 
retinas and graded changes are seen in other genotypes, generally: R90W/W < P10 E168d2/+, 
E168d2neo/+ < P21 E168d2/+, E168d2/+ < P10, P21 R90W/+ (Fig 3.6A).  Comparison to the 
retinal expression of P21 Nrl KO mice as determined by RNA-Seq10, in which rods are 
converted to a 'cone-like' fate11, shows that genes in Group 1 are comprised of genes that are 
both enriched in rods (Fig 3.6A, Log2(FC WT/Nrl KO) column, purple color) or enriched in cones 
(Fig 3.6A, Log2(FC WT/Nrl KO) column, green color).  Additionally, comparison of genes to the 
genomic binding patterns of CRX7 and NRL8 reveal a high degree of CRX binding was 
associated with genes in group 1 in both WT (72%) and Nrl KO (57%) retinas and NRL binding 
in WT (76%) retinas (Fig 3.6A, NRL ChIP and CRX ChIP columns).  This suggests a large 
percentage of genes in Group 1, the most strongly downregulated set of genes, are direct 
targets of CRX and NRL in vivo.  G:profiler (http://biit.cs.ut.ee/gprofiler/) pathway analysis shows 
that genes in Group 1 are highly associated with photoreceptor specific processes including: 
visual perception, phototransduction, photoreceptor outer segment, retina development in 
camera-type eye etc. (Fig 3.6B).  The Cell Specific Expression Analysis tool (CSEA, 
http://genetics.wustl.edu/jdlab/csea-tool-2/), which associates inputted gene lists with 
expression profiles from 27 different brain cell-types (Fig 3.6 C), suggests that genes from 
Group 1 are highly associated with rod and cone-specific expression.   
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 Group 6 is primarily composed of genes that are the most upregulated across 
genotypes, excluding group 8 which was largely composed of non-retinal genes attributable to 
sample contamination (Fig 3.7).  Expression is generally more upregulated in P10 E168d2/d2 
mice, suggesting that both downregulation and upregulation of gene expression are most 
severe in E168d2/d2 mice (Fig 3.7A).  Graded changes are seen amongst genotypes, similar to 
Group 1, but appear to be more age dependent than genotype dependent with P10 showing 
greater changes than P21 samples (Fig 3.7A).  Comparison to gene expression in P21 Nrl KO 
retinas shows that genes in Group 6 are primarily associated with genes that are either not 
enriched in rods vs. cones or are specifically enriched in cones (Fig 3.7A, Log2(FC WT/Nrl KO) 
column, green color).  A low degree of CRX DNA-binding in WT (24%) and Nrl KO (35%) retinas 
and reduced percentage of NRL DNA-binding in WT (57%) retinas compared to genes in group 
1.  This suggests that the genes in Group 6 are largely indirect targets of CRX and 
misregulation may be due to secondary effects.  G:Profiler analysis shows that genes in Group 
6 are associated with 3 GO processes: ion transport, basement membrane and transporter 
activity (Fig 3.7B).  Upregulation of genes involved in ion transport and transporter activity are of 
interest as phototransduction is driven by cGMP-mediated ion channel response.  Of particular 
interest is Cngb3 (NM_013927), a cone-specific cyclic nucleotide-gated (CNG) channel that has 
been associated with achromatopsia and cone degeneration12,13.  The CSEA tool indicates 
association of genes in Group 6 most strongly with cones but also several other brain cell types 
from different brain regions (Fig 3.7C).  It is unclear if the association of Group 6 genes with 
cone-specific expression is indicative of E168d2 and R90W photoreceptors adopting a more 
'cone-like' state or shared developmental defects with photoreceptors in Nrl KO retinas.  
However, none of the 'cone-specific' genes identified in Group 6 are associated with cone 
phototransduction.  CSEA results suggest that genes in Group 6 are not exclusively associated 
with photoreceptor expression, particularly for rods.  Overall analysis of genes in Groups 1 and 
6 indicate the downregulated genes in E168d2 and R90W mice are primarily direct targets of 
Chapter III 
 
85 
 
CRX and NRL and are associated with photoreceptor-specific functions, while upregulated 
genes are largely indirect targets of CRX and are largely not associated with photoreceptor 
function.               
 
Discussion 
 Our results indicate the increased utility of next-generation RNA sequencing over 
microarray platforms.  Parallel comparison of gene expression by RNA-Seq and microarray in 
homozygous E168d2 and R90W mice, show that RNA-Seq yields greater numbers of 
differentially expressed genes and improves the detection of genes expressed at low levels or 
by a small percentage of the cell population, namely cones in the mouse retina.  Cross platform 
analysis shows a high degree of overlap (Fig 3.2), suggesting that comparing results between 
platforms is possible.  Discussion in this section will focus on results from RNA-Seq experiments 
due to their improved sensitivity. 
 Expression profiling of E168d2 and R90W mouse retinas suggests that CRX[E168d2] 
impairs target gene transcription in a dosage dependent manor, while CRX[R90W] weakly 
promotes expression.  In both heterozygous and homozygous E168d2 and R90W mouse 
retinas, the expression of a greater number of genes was disrupted and the expression of 
shared genes was more dramatically altered in E168d2 retinas.  Comparison of expression in 
E168d2/d2 to Crx KO retinas by microarray, immunofluorescence and qRT-PCR showed that 
many genes were expressed lower in E168d2/d2 including: Rho, Arr3, Ramp3, Drd4, Cpm, and 
Pde6c.  This suggests CRX[E168d2] protein had an antimorphic effect on the expression of genes 
even in the complete absence of WT CRX, possibly by interfering with other co-factors like the 
homeodomain transcription factor OTX2.  Supporting this hypothesis, removal of one allele of 
Otx2 from the -/- mouse produced a severe phenotype similar to homozygous E168d2 mice14,15.  
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Since OTX2 and CRX have overlapping spatial and temporal roles in retinal development and 
share DNA binding domain homology, it is possible that CRX[E168d2] interfered with OTX2 activity, 
resulting in a stronger phenotype than -/-.  Expression of CRX target genes in R90W/W was 
largely improved compared to E168d2/d2, correlating with modestly improved morphology (Fig 
3.3C, F). 
   Expression profiling of heterozygous E168d2, E168d2neo and R90W mouse retinas at 
P10 and P21 reveal distinct changes in gene expression that correlate with phenotypic severity.  
Downregulation of CRX target genes associated with photoreceptor function was seen in 
E168d2/+ and E168d2neo/+ at both time points (Fig 3.4), while few genes were downregulated 
in R90W/+ retinas.  While many critical photoreceptor genes are expressed lower in E168d2/+ 
compared to E168d2neo/+, overall their expression profiles appear strikingly similar and very 
few genes were found to be more than 2-fold different between them (Fig 3.4A-B, D-E, H-I, K-L, 
Fig 3.5A-B).  This suggests that the dramatically improved phenotype of E168d2neo/+ in 
comparison to E168d2/+ is related to only modest improvements in the expression of CRX 
target genes.  This finding could have significant impact when considering therapeutic strategies 
as small gains in CRX target gene transcription could yield large gains in retinal phenotype.  
 Hierarchical clustering of expression data over all genotypes reveals subsets of genes 
with characteristic expression patterns with distinct associations with cellular pathways, CRX 
and NRL DNA-binding and cell-type specific expression (Fig 3.6, 3.7).  Genes within the group 
showing the strongest downregulation across genotypes are associated with pathways related 
to the function of photoreceptors in vision, a high percentage of CRX and NRL binding, and 
exhibit either rod or cone-specific enrichment of expression in WT mouse retinas (Fig 3.6A-C).  
Genes within the group showing the strongest upregulation across genotypes are associated 
with pathways related to the function of ion channels, a low percentage of CRX and NRL 
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binding, and exhibit either cone-specific enrichment or are not enriched in WT retinas (Fig 3.7A-
C).   
Overall our results suggest that mutations affecting the function of CRX primarily cause 
the downregulation of direct target genes, which are highly associated with visual processes in 
photoreceptors.  Phenotypic differences between the E168d2, E168d2neo and R90W mouse 
models are due to graded changes in expression in similar sets of genes and small changes in 
expression levels of these genes can have a dramatic effect on retinal phenotype.   
 
For detailed Materials and methods see Appendix B. 
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Tables 
 
 
Table 3.1) Downregulated RP, CoRD, LCA disease genes in P10 homozygous Crx 
E168d2neo and R90Wneo mice.  List of human genes associated with RP, CoRD or LCA 
whose mouse homologs were identified as being significantly downregulated in P10 microarray 
of P10 E168d2neo/neo or R90Wneo/Wneo mice. 
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Table 3.2) Read statistics from RNA-Seq experiments.  Read information for individual 
samples from Illumina Hi-Seq runs. 
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Table 3.3) qRT-PCR Expression in P10 mouse retinas.  ^Overall p-value for each primer set 
was tested in heterozygous and homozygous mice; p<0.09 was considered marginally 
significant.  For all comparisons to WT: *p<0.05; reference genes Tuba1b and Ubb. 
  
Chapter III 
 
93 
 
 
 
Table 3.4) qRT-PCR Expression in P21 mouse retinas.  ^Overall p-value for each primer set 
was tested in heterozygous; p<0.09 was considered marginally significant.  For all comparisons 
to WT: *p<0.05; reference genes Tuba1b and Ubb. 
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Figure 3.1) Graded changes in retinal gene expression in homozygous E168d2, R90W 
and -/- mice.  A-B) Venn diagram showing genes differentially expressed at P10 as identified by 
Illumina gene expression mouseRef6 microarray.  E168d2neo/d2neo, R90Wneo/Wneo and -/- 
mice show a high degree of overlap in differentially expressed genes. C) Percentages of 
differentially expressed genes found to be directly bound by WT CRX protein in WT and Nrl KO 
retinas by ChIP-Seq, showing association of differentially expressed genes with direct CRX 
targets. D) Heat map of commonly downregulated genes in E168d2neo/d2neo, R90Wneo/Wneo 
and -/- mice show graded changes in gene expression of commonly downregulated genes.  E) 
Cellular processes associated with commonly downregulated genes, based on gene ontology 
provided by Mouse Genome Informatics, showing a widespread effect of Crx mutations on 
visual and cellular pathways.   
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Figure 3.2) Venn diagrams showing the overlap of differentially expressed genes 
determined by microarray and by RNA-Seq. Venn diagram of showing the number of genes 
>2-fold differentially expressed in RNA-Seq and Microarray experiments in A-B) P10 
E168d2/d2, C-D) P10 R90W/W.  Venn diagram of showing the number of genes >2-fold 
differentially expressed in RNA-Seq in E-F) E168d2/d2 and R90W/W mouse retinas.  
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Figure 3.3) Expression pattern in homozygous E168d2 and R90W mice.  A-B) Volcano 
plots showing the distribution of gene expression in P10 E168d2/d2 (A) and R90W/W (B) mouse 
retinas by RNA-Seq.  Log2 fold-change (FC) is plotted against the strength of significance as 
determined by the -log10 False discovery rate (FDR).  Genes above the horizontal red line are 
significantly differentially expressed in the indicated genotype, compared to WT.  Genes to the 
left of the left-most vertical red line are downregulated and genes to the right of the right-most 
vertical red line are upregulated compared to WT.  12 genes with kown function in rods/cones 
were labels in white to illustrate the patterns on gene expression.  C) Scatter plots of the Log2 
fold-change (FC) to WT of E168d2/d2 vs. R90W/W at P10.  Genes above the top red line are 
expressed >2-fold higher in the genotye indicated on the veritcal axis.  Genes below the bottom 
red line are expressed >2-fold higher in the genotype indicated on the horizontal axis.  D-G) P14 
paraffin embedded sagittal retinal sections of E168d2/d2, R90W/W and -/- mice were stained 
with Rhodopsin (RHO, green) and DAPI (blue), and imaged by wide field fluorescence at 40x.  
Note that RHO is absent in E168d2/d2, while mislocalized to ONL in R90W/W and -/-.  H-K) 
Validation of microarray results by qRT-PCR analyses on selected CRX target genes, Rho, 
Arr3, Opn1mw and Opn1sw in retinas of the indicated mouse strains at P10 shown as FC 
relative to WT. (*p<0.05; Error bars: STDEV).  
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Figure 3.4) Expression patterns in heterozygous E168d2 and R90W mice.  A-B) Volcano 
plots showing the distribution of gene expression in P10 E168d2/+ (A) and R90W/+ (B) mouse 
retinas by RNA-Seq.  Log2 fold-change (FC) is plotted against the strength of significance as 
determined by the -log10 False discovery rate (FDR).  Genes above the horizontal red line are 
significantly differentially expressed in the indicated genotype, compared to WT.  Genes to the 
left of the left-most vertical red line are downregulated and genes to the right of the right-most 
vertical red line are upregulated compared to WT.  12 genes with known function in rods/cones 
were labeled in white to illustrate patterns in gene expression. D-E) Venn diagrams showing the 
number of genes >2-fold differentially expressed in P10 E168d2/+ vs. E168d2neo/+ and F-G) 
E168d2/+ vs. R90W/+ mouse retinas.  H-J) Volcano plots showing the fold change and 
significance by FDR for all genes in P21 E168d2/+ (H), E168d2neo/+ (I) and R90W/+ (J) mouse 
retinas.  12 genes with known function in rods/cones were labeled in white to illustrate patterns 
in gene expression. K-L) Venn diagrams showing the number of genes >2-fold differentially 
expressed in P21 E168d2/+ vs. E168d2neo/+ and M-N) E168d2/+ vs. R90W/+ mouse retinas. 
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Figure 3.5) Retinal gene expression in heterozygous E168d2, E168d2neo and R90W 
mouse retinas.  A-D) Scatter plots of the Log2 fold-change (FC) to WT of E168d2/+ vs. 
E168d2neo/+ at P10 (A) and P21 (B) and of E168d2/+ vs. R90W/+ at P10 (C) and P21 (D).  
Genes above the top red line are expressed >2-fold higher in the genotye indicated on the 
veritcal axis.  Genes below the bottom red line are expressed >2-fold higher in the genotype 
indicated on the horizontal axis.  E-H) Paraffin embedded sagittal retinal sections of 1mo WT 
and the indicated heterozygous mutant mice were stained with mouse monoclonal anti-
Rhodopsin RetP-1 antibody (Chemicon) (RHO, red) and DAPI nuclear conterstaining (blue), and 
imaged by widefield fluorescence at 40x.  Scale bars 25μM.  E168d2/+ shows reduced RHO 
staining intensity in rod OS’s and mislocalized RHO in ONL.  I-L) qRT-PCR analysis of four CRX 
target genes, Rho, Arr3, Opn1mw, Opn1sw in the indicated heterozygous mice at P10 and P21 
(*p<0.05; bracketed *FDR p<0.09; Error bars: SEM). 
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Figure 3.6)  Patterns in Group 1 genes in E168d2 and R90W retinas.  A) Hierarchical cluster 
analysis of gene expression in P10 and P21 E168d2 and R90W mouse retinas.  Log2 fold-
change (FC) to WT is shown in a graded color heat map with blue being downregulated and red 
being upregulated (upper left).  Genotypes and ages are shown for each column and gene 
symbols are listed for each row.  Gene subsets were selected based on overall expression 
patterns among genotypes.  Group 1 showed the most downregulated expression among 
differentially expressed genes.  Heatmaps were paired with RNA-Seq expression in P21 Nrl KO 
mouse retinas.  Genes downregulated in Nrl KO are shown in purple and upregulated in green.  
Enrichment of DNA-binding for each genes by NRL in P21 WT mouse retinas and CRX in WT 
and Nrl KO mouse retinas as determined by ChIP-Seq are shown with black being the highest 
enrichment.  B) G:profiler pathway analysis showing cellular pathways (GO processes) that are 
significantly associated with genes in Group 1.  The Pvalue, GO process ID, Pathway name and 
the genes in Group 1 associated with each GO process are listed.  C) Cell specific expression 
analysis (CSEA) results showing the cell-type specific expression in WT mouse retinas for 
genes in Group 1.  Colored hexagons indicate cell-types that have been associated with the 
specific expression of queried genes, darker colors indicate higher significance.  Hexagon rings 
indicate the specificity of gene expression with genes belonging to the inner-most rings 
associated with the most cell-type specific gene expression and outer-most rings associated 
with the least specific expression.  
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Figure 3.7)  Patterns in Group 6 genes in E168d2 and R90W retinas.  A) Hierarchical cluster 
analysis of gene expression in P10 and P21 E168d2 and R90W mouse retinas.  Log2 fold-
change (FC) to WT is shown in a graded color heat map with blue being downregulated and red 
being upregulated (upper left).  Genotypes and ages are shown for each column and gene 
symbols are listed for each row.  Gene subsets were selected based on overall expression 
patterns among genotypes.  Group 6 showed the most upregulated expression among 
differentially expressed genes.  Heatmaps were paired with RNA-Seq expression in P21 Nrl KO 
mouse retinas.  Genes downregulated in Nrl KO are shown in purple and upregulated in green.  
Enrichment of DNA-binding for each genes by NRL in P21 WT mouse retinas and CRX in WT 
and Nrl KO mouse retinas as determined by ChIP-Seq are shown with black being the highest 
enrichment.  B) G:profiler pathway analysis showing cellular pathways (GO processes) that are 
significantly associated with genes in Group 6.  The Pvalue, GO process ID, Pathway name and 
the genes in Group 6 associated with each GO process are listed.  C) Cell specific expression 
analysis (CSEA) results showing the cell-type specific expression in WT mouse retinas for 
genes in Group 6.  Colored hexagons indicate cell-types that have been associated with the 
specific expression of queried genes, darker colors indicate higher significance.  Hexagon rings 
indicate the specificity of gene expression with genes belonging to the inner-most rings 
associated with the most cell-type specific gene expression and outer-most rings associated 
with the least specific expression.  
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Introduction- Allele-specific overexpression of CRX truncation mutations 
 E168d2 mice express abnormally high levels of both mutant mRNA and its protein 
product.  We predicted that overexpression was related to the intrinsic properties of E168d2 
mRNA, driven either by transcription efficiency or post-transcription mRNA stability.  Since a 
previous study of human CRX mutants in Drosophila shows that another frameshift mutation 
I138fs48 is overly stable1, we also wanted to examine whether allelic expression imbalance may 
be a general characteristic of frameshift CRX mutations.  For this reason we sought to 
investigate if mutant Crx overexpression is conserved by investigating the expression of Crx in a 
feline model of CRX retinopathy, CrxRdy, which carries a similar type frameshift mutation as 
E168d2.  We also examined mutations in vitro to determine if overexpression is a common 
feature of human disease-causing mutations from this class.  Additionally, we investigated the 
mechanism of E168d2 overexpression by assessing in the post-transcriptional stability of the 
mutant transcript both in vitro and ex vivo.         
While frameshift mutations that generate early stop codons can lead to transcript 
degradation in a well-characterized process called nonsense-mediated mRNA decay (NMD)2, 
there is little previous evidence of these types of mutations causing transcript over-stability.  
Therefore, allele-specific overexpression of Crx transcripts may indicate not only a novel 
mechanism of disease but may be interesting biologically.      
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Results 
4.1. Allelic expression levels of mouse, feline and human CRX mutants 
4.1.i) Phenotype and expression of Crx mRNA and protein in the feline disease model, 
CrxRdy  
 The CrxRdy cat carries the frameshift mutation Crx n.546delC and is associated with 
dominant and progressive retinopathy characteristic of LCA3–7.  Crx n.546delC results in the 
introduction of an early stop-codon and was predicted to lead to the expression of a truncated 
CRX protein that was only 14 amino acids longer than CRX[E168d2].  Assessment of cone and rod 
morphology in heterozygous CrxRdy cats at 6wk by immunofluorescent staining of sagittal retinal 
sections with mCARR and Rho antibodies reveals striking similarity to the CrxE168d2 mouse 
phenotype at 1mo (Fig 4.1A-H).  6wk heterozygous CrxRdy cats have noticeably fewer mCARR 
positive cells compared to WT (Fig 4.1D vs. C).  While the ONL maintains normal thickness 
through 6wk, rod outer segments are shortened and Rhodopsin is mislocalized to the 
nucleus/cell body (Fig 4.1H vs. G).  The morphology of CrxRdy cones and rods suggest that, 
similar to E168d2 mice, both photoreceptor types are affected and cone loss occurs earlier and 
is more severe.  Thus, the CrxRdy cat model closely resembles the phenotype of E168d2 mice, 
indicating it is a well-matched large animal model. 
 The expression of CRX protein was assessed by Western blot at P1, P14, 6wk, 12wk 
and 20wks in WT and CrxRdy cats (Fig 4.1I).  CrxRdy cats express both WT and a truncated 
mutant CRX at all ages (Fig 4.1I).  Similar to E168d2 mice, the truncated mutant CRX protein in 
CrxRdy cats is expressed at higher levels than the full-length WT CRX protein.  By 20wks of age, 
the expression of WT CRX is barely detectable, while expression of the truncated protein is still 
robust.  The expression level of Crx mRNA was determined by qRT-PCR at P14, 6wk and 20wk 
in WT and heterozygous CrxRdy cats (Fig 4.1J).  The expression of total Crx mRNA was 
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measured since we were unable to design allele-specific qRT-PCR primers, as we did for 
E168d2 and R90W mice (Fig 2.2J).  Total Crx was overexpressed by ~2-fold in heterozygous 
CrxRdy cats compared to WT cats at each time point by (Fig 4.1J).  This is similar to the level of 
total Crx in heterozygous E168d2/+ mice.  Collectively, these results show that both E168d2 
mice and CrxRdy cats have allele-specific overexpression of mutant Crx mRNA and protein, 
suggesting that this characteristic is conserved between the two animal models. 
 
4.1.ii. Mouse, human and cat truncating Crx mutations are overexpressed in vitro 
 To test if other truncating mutations are also overexpressed, we assessed their 
expression in vitro by Western blot and qRT-PCR.  First, however, it was necessary to 
determine whether E168d2 and Rdy expression in vitro recapitulated expression patterns 
observed in vivo in the mouse and cat models.  Mouse and human Crx WT, E168d2 and R90W 
and cat Crx WT and Rdy were each cloned into the pCAGIG plasmid, in which expression is 
driven by the pCAG promoter and co-expresses Gfp from an internal ribosomal entry site.  
Equal concentrations of each plasmid were independently transfected into HEK 293 cells, 
cultured for 48hrs and nuclear protein was collected for Western blot experiments.  Similar to 
the pattern in E168d2 and R90W mouse retinas, E168d2 protein level was elevated and R90W 
protein level was reduced, compared to WT in vitro (Fig 4.2A).  The cat CRX Rdy protein was 
also elevated compared to cat WT in vitro, similar to mutant expression in CrxRdy cats (Fig 4.2B).  
Since E168d2 and Rdy proteins were overexpressed even when expression was driven by a 
common promoter in vitro, it suggest that in vitro transfection accurately recapitulated in vivo 
expression patterns and is a valid method for assessing the expression patterns of Crx mutants.  
Subsequently, the expression of human CRX E168d2 and R90W were tested.  Similar to mouse 
E168d2 and R90W proteins, E168d2 protein was elevated and R90W was reduced compared to 
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WT level in vitro (Fig 4.2C), suggesting expression patterns were conserved between mouse 
and human mutants.  Finally, early stop codons were cloned into an Xpress tagged human CRX 
gene at the amino acids number 107, 160, 168, 208 and 254 (Fig 4.2D) and the expression 
levels of their mRNA and protein were tested.  These constructs encode the full-length human 
CRX transcript but result in the translation of a truncated CRX protein, comparable to frameshift 
truncation mutations.  Plasmids were designated as 'U constructs' since they represent 
truncation mutations that convert portions of CRX's coding region into a novel 3' UTR.  Each of 
the truncated U constructs tested expressed mutant CRX at significantly higher levels compared 
to WT (Fig 4.2E).  The U constructs U160, U168 and U208 also expressed protein at higher 
levels compared to WT (Fig 4.2F).  The constructs U107 and U254 did not overexpress CRX 
protein, despite overexpressing CRX mRNA (Fig 4.2F vs. E), this suggests that the stability of 
U107 and U254 proteins may have been compromised.  These results require further 
confirmation since they were performed in individual transfections making it impossible to 
control for variations in transfection efficiencies.  Experiments are being designed to test 
expression of multiple constructs co-transfected into a single population of cells, which should 
improve the reliable of results.  Collectively, these results support our hypothesis that mutant 
CRX overexpression is a common characteristic among several truncating mutations and is 
conserved between mouse, cat and human CRX.   
 
4.2. Assessment of the stability of WT and mutant Crx mRNA 
    To determine if mRNA stability was a mechanism for the overexpression of E168d2, 
we measured the degradation of Crx transcripts in vitro and in vivo over time.  To control for 
potential inconsistencies among transfection experiments, unique 10bp barcodes were inserted 
into the 3' tail of human Crx WT and E168d2 constructs (Fig 4.3A) to allow for the analysis of 
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transcripts from co-transfected plasmids by qRT-PCR.  To control for the possibility that 
barcodes affected mRNA expression or stability, CRX WT was tagged with 4 unique barcodes 
and E168d2 was tagged with 2 bar codes (Table 4.1) and the combined results were analyzed.  
CRX WT and E168d2 constructs tagged distinct barcodes were co-transfected in pairs into HEK 
293 cells.  After 48hrs, transfected cells were treated with Actinomycin D, which blocks mRNA 
transcription8–11 and incubated then harvested at 4hrs or 8hrs.  mRNA was collected and the 
expression of CRX mRNA was determined by qRT-PCR, results were normalized to the 
expression level at time 0hrs.  Fig 4.3B shows that WT CRX mRNA transcripts were degraded 
by ~30% at 4hrs and ~42% at 8hrs, while E168d2 only degraded by ~4% at 4hrs and ~17% at 
8hrs.  Thus, E168d2 transcripts degraded more slowly than WT CRX suggesting that E168d2 
transcripts may be more stable that WT transcripts.  The stability of CRX WT, E168d2 and 
R90W mRNA was also tested ex vivo by treating explanted P10 retinas from WT and 
homozygous E168d2/d2 and R90W/W mice with Actinomycin D.  Crx WT and R90W showed 
comparable degredation at 4hrs (WT ~43%, R90W ~57%) and 8hrs (WT ~70%, R90W ~65%) 
(Fig 4.3C).  In contrast, E168d2 transcripts  were less degraded at 4hrs (~30%) and 8hrs 
(~30%) (Fig 4.3C), suggesting that E168d2 transcripts degrade at a slower rate than either Crx 
WT or R90W transcripts ex vivo.  Degradation of WT and E168d2 transcripts was also assessed 
in heterozygous E168d2/+ retinas and allele-specific primers were used to assess the levels of 
each mRNA species.  WT transcripts were more degraded at 4hrs (WT ~35%, E168d2 21%) 
and 8hrs (WT ~55%, E168d2 ~15%), suggesting that E168d2 degrades at a slower rate than 
Crx WT transcripts within the same retinal cells.  This additionally suggests that the slower 
degradation of E168d2 is not due to the disease state in E168d2 retinas but is likely due to 
properties intrinsic to E168d2 transcripts.  Collectively, these results indicate the E168d2 mRNA 
is more stable than Crx WT mRNA, implicating intrinsic RNA stability as a likely mechanism of 
mutant allele overexpression in E168d2 mice. 
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Discussion 
 Our results show that overexpression of mutant Crx is a common characteristic among 
several truncating Crx mutations and is conserved between mice, cats and humans.  E168d2 
mice and CrxRdy cats have similar patterns of Crx mRNA and protein expression (Fig 4.1A-J), 
demonstrating both that allelic-expression imbalance isn't restricted to a particular Crx mutation 
and that it is conserved between species.  This strengthens the utility of both the E168d2 mouse 
and CrxRdy cat as matched large and small animal models for studying common mechanisms of 
disease for Crx mutations of this type.  In vitro testing of human CRX truncation mutations 
matched the overexpression patterns in mouse and cat animal models (Fig 4.2A-C) suggesting 
that mutants of this type could be conserved for human mutants as well.  The overexpression of 
E168d2 was linked to increased mRNA stability compared to WT Crx (Fig 4.3A-D), suggesting 
that overexpression may be caused by alteration in the intrinsic properties of mutant Crx 
transcripts.  In contrast, mouse and human R90W protein levels were decreased (Fig 4.2A) and 
its mRNA transcript stability was not significantly affected (Fig 4.3C).  This suggests that 
mutations of this type may not match the patterns observed in truncated mutants.  Overall these 
results support the hypothesis that truncation mutations within the C-terminal region of Crx alter 
mRNA stability leading to the overexpression of the mutant Crx allele.  This characteristic is 
conserved among several truncating mutants and between species including humans, 
suggesting it may play an important role in disease.  These results also reveal how accurate 
animal models of disease can be used to identify previously unknown mechanisms of disease.  
Results also have implications for designing mutation class-specific therapy strategies, possibly 
targeting mutant allele expression.       
 For detailed materials and methods please see Appendix B 
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Table 4.1) Barcoded human Crx plasmid constructs.  Table shows the unique barcodes 
inserted into the 3' end of an Xpress tagged human CRX expressed from the pcDNA3.1hisc 
vector. 
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Figure 4.1) Photoreceptor morphology and CRX expression in CrxRdy cats.  A-D) Cone 
morphology in 1mo WT and E168d2/+ mice (A-B) and 6wk WT and CrxRdy/+ cats (C-D) as 
determined by immunofluorescent staining for mCarr (green) of retinal sagittal sections, 
counterstain: DAPI (blue).  Rod morphology in 1mo WT and E168d2/+ mice (E-F) and 6wk WT 
and CrxRdy/+ cats (G-H) as determined by immunofluorescent staining for Rho (red) of retinal 
sagittal sections, counterstain: DAPI (blue).  Scale bars: 25µM.  I) Western blots of nuclear 
protein lysates from P1, P14, 6wk, 12wk and 20wk old WT and CrxRdy/+ cat retinas showing 
expression of CRX and β-actin.  J) qRT-PCR results from 2wk, 6wk and 20wk old WT and 
CrxRdy/+ cat retinas showing the normalized expression of total Crx mRNA.  Error bars: SEM. 
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Figure 4.2) Expression of Crx mutants mRNA and protein in vitro.  A-C) Western blots 
showing the expression of WT and mutant mouse, cat and human CRX proteins from pCAG 
constructs in vitro.  β-actin expression is shown below as a loading control.  'α' symbol indicates 
antibody against the indicated gene.  D) Schematic showing the plasmid design of human CRX 
'U constructs'.  From top to bottom: CRX- WT, U254, U208, U168, U160 and U107.  CRX 
protein domains associated with DNA binding (blue) and transactivation (red) are highlighted 
above.  E) Quantification of human CRX 'U construct' mRNA expression in vitro measured by 
qRT-PCR.  Results were normalized to Ubb and Gapdh.  F) Quantification of human CRX 'U 
construct' protein expression in vitro measured by Western blot as determined by Xpress level 
normalized to β-ACTIN (β-ACT).  Error bars: SEM, *P-val<0.05          
 
 
 
 
  
Chapter IV 
 
121 
 
 
Chapter IV 
 
122 
 
 
Figure 4.3) Stability of Crx mRNA in vitro and ex vivo.  A) Schematic showing the design of 
barcoded human CRX WT and E168d2 'U constructs'.  10 base pair (bp) barcodes were 
inserted into the 3' end of human WT (4 distinct barcodes) and E168d2 'U constructs' (2 distinct 
barcodes).  WT and E168d2 construct carrying distinct barcodes were co-transfected in pairs for 
the analysis of expression within the same cell population.  Co-transfected barcoded WT and 
E168d2 constructs were treated with Actinomycin D for 4hrs or 8hrs and harvested.  B) qRT-
PCR showing the fold-change (FC) of CRX mRNA at 4hrs and 8hrs following the addition of 
Actinomycin D from transfected HEK 293 cells. Results were normalized to Ubb and Gapdh 
levels and shown relative to CRX expression at 0hrs.  C) qRT-PCR showing the fold-change 
(FC) of Crx mRNA at 4hrs and 8hrs following the addition of Actinomycin D to P10 retinal 
explants from the indicated genotype.  D) qRT-PCR showing the fold-change (FC) of Crx mRNA 
at 4hrs and 8hrs following the addition of Actinomycin D to P10 retinal explants from E168d2/+ 
mice.  Allele-specific primers (Table 2.1) were used to selectively amplify WT and E168d2 
transcripts.  The height of the bar indicates the expression of total Crx and the colors indicate 
the portion of expression composed of WT (blue) and E168d2 (red) transcripts.  Error bars: 
SEM, *P-val<0.05. 
           
 
 
 
 
  
 
 
 
 
Chapter V 
- 
Assessment of Potential Therapeutic 
Strategies for CRX-Associated 
Retinopathies 
 
Author: Nicholas Tran 
 
 
 
 
Experiments and analysis contained within this chapter were performed by 
Nicholas Tran.  Viral vectors for gene therapy experiments were subcloned and 
packaged by Sanford Boye and William Hauswirth (University of Florida). 
Chapter V 
 
124 
 
Introduction: Hurdles to developing mechanism-based therapeutic strategies for CRX-
associated retinopathies 
 Currently, the vast majority of genetic retinopathies have few, if any, viable therapeutic 
strategies.  This is in part because the enormously diverse genetic causes of retinopathies have 
made it difficult to generate accurate animal models to understand disease pathology and 
design appropriate treatments.  The E168d2 and R90W mouse models, along with the CrxRdy 
cat model, provide accurate disease models for multiple forms of CRX-associated disease.  
However, the generation and characterization of appropriate animal models is only the first 
hurdle to developing effective therapy for degenerative retinopathies. 
 The next challenge in developing effective therapy is delivering therapeutic agents to 
photoreceptor cells.  The photoreceptor layer is completely avascular and is separated from the 
choroid by the blood-retina barrier.  This makes small molecule drug delivery difficult unless the 
drug is taken up by the supporting retinal epithelial layer (RPE), which directly contacts 
photoreceptors, or is directly inserted into the eye, a highly invasive procedure.  Nonetheless, 
progress in small molecule approaches has been made in both of these instances.  Retinoids, 
critical components of phototransduction, that are naturally trafficked to the RPE where they are 
processed and delivered to the photoreceptors, have been used to treat congenital blindness, 
measles related childhood blindness and retinitis pigmentosa1–3.  A variety of retinal diseases 
have been treated using slow-release capsules containing small molecule drugs or recombinant 
proteins proving effective in improving retinal function or photoreceptor survival4,5.    
 Retinopathy is directly linked to mutations in genes whose function cannot be replaced 
by therapeutic agents.  Targeting general pathways using drugs are often insufficient to 
completely rescue photoreceptor function and survival.  This is expected to be the case for 
CRX-associated disease, since CRX plays such a critical role in photoreceptor transcription.  
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Additionally, drug-based treatment approaches require repeated dosing often with undesirable 
side effects or prohibitive costs.  Substantial progress has been made in gene replacement 
strategies using recombinant adeno-associated virus (rAAV) mediated gene therapy6–14.  The 
retina is an ideal tissue for targeting rAAV gene therapy, since it is immune-privileged, part of a 
self-contained accessible organ and has good epitope specificity for rAAV infection.  Despite 
these advantages, there is still a need to identify rAAV serotypes which improve infection 
efficiencies and reduce toxicity.  Additionally, with genes like CRX, that regulate the expression 
of many downstream target genes, the expression level needs to be carefully titrated as WT 
overexpression could be just as damaging as the disease itself.       
 Since retinopathies frequently result in the degeneration of photoreceptors, there is often 
a limited time window for effective delivery of therapeutic reagants.  While some progress has 
been made in cell based therapies involving the transplantation, integration and differentiation of 
stem cells into mature photoreceptors, implantation rates are low and even successful 
approaches have only yielded modest gains in retinal function15,16.  Nonetheless, cell 
replacement therapies may develop into viable treatment options in advanced retinal 
degeneration in the future. 
 Currently, there are no treatment strategies for CRX-associated diseases.  Since CRX 
influences many cellular processes, designing targeted therapy is exceptionally difficult.  The 
availability of phenotypically and mechanistically distinct models for CRX-associated disease 
greatly improve our ability to develop novel therapies.  E168d2, E168d2neo and R90W present 
unique mechanistic challenges for therapy to address.  Like -/- mice, E168d2/+, E168d2/d2 and 
R90W/W mice all have highly abnormal photoreceptor morphology and undergo rapid 
degeneration, which may restrict the time course and effectiveness of treatment.  The improved 
phenotype of E168d2neo/+ mice, compared to E168d2/+, provides evidence that gene 
replacement strategies that shift the ratio of WT to mutant CRX could be effective at improving 
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vision and promoting rod and cone survival in cases were a mutant protein is toxic and/or 
overexpressed.  Previous studies have shown this strategy to be effective in treating a 
dominant-negative adRP RHO animal model9,17.  Lastly, the similarity of the E168d2/+ mouse 
and the CrxRdy cat provide excellently matched small and large animal models.  Therapies that 
are proven to be effective in the E168d2/+ mouse can immediately be tested in the CrxRdy cat, 
which improves our ability to develop translational therapies. 
 Here we present the preliminary testing of a small molecule based approach using 13-
cis retinoic acid (13-cis RA) (Sigma-Aldrich) to target the visual cycle, and rAAV-mediated 
approaches for CRX gene delivery and mutant protein silencing in the retina.   
 
Results 
5.1. Preventing retinal degeneration by targeting the visual cycle 
 Analysis of the gene expression profiles of E168d2 and E168d2neo retinas identified 
many photoreceptor specific genes that are downregulated including genes involved in retinoid 
recycling like Rdh12, Irbp and Abca4.  Genes involved in retinoid recycling are critical for the 
sensitivity of photoreceptors to light-induced stress due to their role in processing retinoid by-
products of phototransduction18–23.  This led to the hypothesis that heterozygous E168d2 and 
E168d2neo mice might have increased sensitivity to light-induced degeneration.  To test this 
hypothesis, we subjected adult WT, E168d2/+ and E168d2neo/+ mice to an 8hr 11.5-13.5KLUX 
light damage (LD) treatment.  After 7 days of recovery in 12hr light-dark ambient light 
conditions, mice were sacrificed and retinal morphology was assessed by histological H&E 
staining of paraffin embedded retinal sagittal sections.  All mice tested were on a congenic 
C57BL6/J background, which is highly resistance to light damage18.  As expected, no thinning of 
the ONL was observed in LD treated WT mice compared to littermates raised under normal light 
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conditions (Fig 5.1 D vs. A).  Surprisingly, however, E168d2neo/+ and E168d2/+ mice differed in 
their susceptible to light damage.  E168d2neo/+ mice show reduced outer segment length and 
thinning of the ONL following light exposure (Fig 5.1 E vs. B), suggesting E168d2neo sensitized 
the mice to light-induced degeneration.  In contrast, E168d2/+ mice were minimally affected by 
light damage (Fig 5.1 F vs. C), suggesting these mice were not sensitized to light-induced 
degeneration.  These results suggest that despite expressing the same mutant CRX protein, 
E168d2neo/+ and E168d2/+ mice were differentially sensitized to light-induced retinal 
degeneration. 
 To test if the increased sensitivity to light damage in E168d2neo/+ mice was linked to the 
retinoid pathway, mice were treated with 13-cis RA.  13-cis RA blocks the visual cycle in the 
RPE24, leading to decreased burden on the retinoid pathway in photoreceptors.  Targeting the 
visual cycle using the retinoids 13-cis RA or retinalymine has been shown to be effective at 
preventing light-induced degeneration3,18,20,24–26.  Light-induced degeneration is associated with 
the accumulation of toxic by-products including A2E derived from inactivated all-trans 
retinal3,18,20,22,24–27.  Drugs that inhibit the visual cycle reduce the amount of active 13-cis retinal 
that is delivered to the photoreceptors and hence reduce the burden on the recycling and 
clearance of inactivated retinoids.  Mice were treated 12hrs and redosed 30min before LD 
treatment.  13-cis RA did not have any effect on WT and E168d2/+ retinal morphology following 
LD treatment (Fig 5.1 H vs. G & M vs. L), which were not sensitized to light damage.  In 
E168d2neo/+ mice, however, 13-cis RA treatment preserved retinal morphology following LD 
treatment compared to DMSO controls (Fig 5.1 J vs. I), suggesting 13-cis RA was protective for 
E168d2neo/+ photoreceptor survival.  Retinal function of 13-cis RA treated and DMSO treated 
E168d2neo/+ mice was measured using ERG's 7 days after LD.  13-cis RA treatment of 
E168d2neo/+ reduced the loss of rod and cone function following LD exposure (Fig 5.1N-P 
green vs. red lines), suggesting 13-cis RA protected retinal function from light-induced damage.  
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Collectively, light damage experiments reveal that E168d2neo/+ and E168d2/+ mice are 
differentially susceptible to light-induced retinal degeneration, suggesting distinct pathways to 
degeneration in these mice.  As E168d2/+ do not have increased sensitivity to light damage but 
have expensive photoreceptor degeneration, E168d2/+ were dark-reared for 3mo to see if 
degeneration was dependent on light conditions.  E168d2/+ mice raised in constant darkness 
had similar morphology to littermates raised under normal light conditions (Fig 5.1Q), 
suggesting degeneration was light-independent.  Overall, results suggest that photoreceptor 
degeneration in E168d2neo/+ mice is accelerated by intense light exposure, while 
photoreceptor degeneration in E168d2/+ is light-independent.          
 
5.2.  Improving visual function by rAAV-mediated gene delivery 
 The graded phenotypes of E168d2/+ and E168d2neo/+ mice suggest modulating the 
ratios of WT:mutant CRX might be effective at improving retinal integrity and function.  The 
antimorphic nature of this mutant protein may necessitate not only the delivery of a WT copy of 
the CRX gene but also the silencing of the antimorphic allele.  The ability of rAAV-mediated 
CRX and CRX shRNA gene therapy to transduce photoreceptors and affect downstream target 
gene expression was tested.  The effectiveness of CRX gene delivery was first tested in Crx -/- 
mice.  A high titer of rAAV5 carrying 3xFLAG tagged human CRX or Green fluorescent protein 
(Gfp) expressed under the photoreceptor specific Rhodopsin Kinase (GRK) promoter28 were co-
injected into the subretinal space of P0 Crx -/- mice.  Retinas were collected at P21 for 
assessment of morphology and gene expression by fluorescent immunohistochemistry.  Sagittal 
retinal frozen sections were stained with antibodies against FLAG, which marked cells 
expressing delivered CRX, and CARR, a cone-specific CRX target gene which was not 
expressed in uninfected Crx -/- retina (Fig 5.2A).  rAAV infected retinas show expression of Carr 
that was completely restricted to FLAG positive cells (Fig 5.2B, white arrows), suggesting that 
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delivered human CRX was able to drive the expression of the downstream CRX gene CARR in 
Crx -/- retinas.  rAAV5 carrying Crx shRNA/ mCherry expressed under the GRK promoter was 
injected into the subretinal space of P0 WT mice to determine if silencing of Crx expression by 
shRNA was capable of affecting the expression of downstream CRX target genes.  As above, 
eyes were collected at P21 for morphological analysis by immunofluorescence.  Sagittal retinal 
frozen sections were stained with peanut agglutanin (PNA), a marker for all cones, and an 
antibody against CARR.  PNA positive cones expressing mCherry showed were negative for 
CARR (Fig 5.2C, red arrows), suggesting that CRX shRNA effectively downregulated the 
expression of this CRX target genes.  Collectively, these experiments suggest that rAAV-
mediated CRX and Crx shRNA gene therapy was effective at infecting photoreceptors and 
affecting the expression of a CRX target gene, suggesting it may be a viable approach for 
targeted therapy. 
 The greatest limitation of the rAAV5 experiments described above was the low infection 
efficiency of the viral vector.  While local infection rates near the injection site could reach ~50-
60%, overall only ~1-5% of photoreceptors were infected across the entire retina.  Given the low 
infection efficiency, the potential for improving retinal function using rAAV5 CRX gene therapy is 
negligible.  To address this, we sought to identify rAAV serotypes with improved infection 
efficiency in the retina.  To this end, the infection efficiency of several rAAV serotypes carrying 
Gfp expressed under the control of the ubiquitous U11 promoter was tested in WT and Crx -/- 
mice.  Eyes were dissected at P21 and Gfp expression across the retina was imaged.  The 
serotypes rAAV5, rAAV2 triple tyrosine mutant (rAAV2 Trip), and rAAV2 quadruple tyrosine 
mutant (rAAV2 Quad) were found to be capable of infecting WT and Crx -/- photoreceptors (Fig 
5.2D-I).  Similar to previous studies29, rAAV2 Trip gave the highest rate of infection of 
photoreceptors.  rAAV2 Trip expressing Gfp under the control of the GRK promoter showed 
efficient infection of WT, E168d2/+ and Crx -/- retinas (Fig 5.2 J-L), suggesting this rAAV 
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serotype may improve efficacy of rAAV5-mediated gene therapy.  rAAV2 Trip CRX and CRX 
shRNA gene therapy approaches are currently in development in the lab.    
 
Discussion 
 Preliminary testing of therapy approaches aimed at preventing retinal degeneration and 
restoring function demonstrate both the utility of having accurate disease models and the 
significant hurdles still remaining for therapy development.  The dominant retinopathy mouse 
models E168d2 and E168d2neo express the same mutant CRX protein at different levels (Fig 
2.2), correlating with their phenotypic severity.  The distinct phenotypes of these mice was found 
to be associates with small changes in the expression level of a common set of genes (Fig 3.4-
3.7), suggesting critical thresholds for target gene expression and phenotypic severity.  Taking 
into account the similarities of E168d2 and E168d2neo mouse models, it was surprising that 
degeneration in each of these models seems to be driven by different mechanisms.  E168d2/+ 
mouse retinas undergo progressive rapid photoreceptor degeneration under normal light 
conditions (Fig 2.5).  Degeneration was found to be light-independent (Fig 5.1Q) and 
photoreceptors are not sensitized to light damage (Fig 5.1 F vs. C).  In contrast, E168d2neo/+ 
undergo slow degeneration of cones but not rods under normal light conditions (Fig 2.5, Fig 2.8) 
and photoreceptors were highly sensitized to light damage (Fig 5.1 E vs. B).  13-cis RA 
treatment in E168d2neo/+ mice was effective at protecting the retinas from light-induced 
degeneration (Fig 5.1 J vs. I), suggesting that degeneration is associated with the retinoid 
pathway.  E168d2neo/+ mice have significantly higher retinal function than E168d2/+ mice when 
raised under normal light conditions (Fig 2.9), suggesting sensitivity to light damage may have 
requisite levels of baseline retinal function.  These results demonstrate that even reasonably 
similar diseases i.e. dominantly inherited retinopathies caused by the same mutant protein and 
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affecting similar sets of genes, could have vastly different responses to therapy, necessitating 
the careful design and evaluation of therapeutic approaches.            
 Testing of gene delivery approaches in Crx mutant mice currently remain in preliminary 
stages but offers promising results.  First, rAAV5-mediated gene delivery of human CRX to Crx -
/- mouse retinas was shown to drive the expression of the downstream CRX target gene Carr 
(Fig 5.2B).  Second, rAAV5-mediated shRNA knock-down of endogenous Crx was effective at 
downregulating CARR expression in the cones of WT retinas (Fig 5.2C).  These results indicate 
that gene therapy approaches were capable of rescuing or silencing CRX function, suggesting 
that gene therapy is a viable approach for targeting downstream pathways of CRX.  However, 
infection efficiency was too low to significantly affect overall retinal function.  The efficacy of Crx 
gene therapy using an alternate rAAV serotype with improved infection efficiency, rAAV2 Trip, is 
currently being evaluated.  The design of effective gene therapy approaches in E168d2 mice will 
be immediately applicable to the well-matched CrxRdy cat model, improving our understanding of 
its overall effectiveness and safety.   
 
For detailed materials and methods please see Appendix B 
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Figure 5.1) Light-induced retinal degeneration in E168d2 mice.  A-C) Morphology of 6wk old 
WT, E168d2neo/+ and E168d2/+ mouse retinas under normal light conditions, as determined by 
H&E staining of paraffin embedded retinal sagittal sections.  D-F) Morphology of 6wk old WT, 
E168d2neo/+ and E168d2/+ mouse retinas 7 days following 8hr 11-13.5KLUX light damage 
(LD), as determined by H&E staining of paraffin embedded retinal sagittal sections.  H-M) 
Morphology of 6wk old WT, E168d2neo/+ and E168d2/+ mouse retinas 7 days following 8hr 11-
13.5KLUX LD with pre-treatment of 13-cis RA vs. DMSO control, as determined by H&E 
staining of paraffin embedded retinal sagittal sections.  Scale bars: 50µM.  N-P) Scotopic and 
photopic electroretingrams of 6wk old E168d2neo/+ 7 days following 8hr 11-13.5KLUX LD with 
pre-treatment of 13-cis RA (green line) vs. DMSO control (red line) and non-LD control mice 
(blue line).  Q) Morpology of 3mo E168d2/+ mice raised in normal light vs. constant darkness, 
as determined by H&E staining of paraffin embedded retinal sagittal sections.     
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Figure 5.2) Evaluation of rAAV-mediated CRX and Crx shRNA gene therapy approaches.  
A-B) Fluorescent immunohistochemistry showing the expression of delivered 3xFLAG-tagged 
human CRX, as determined by detection with a monoclonal FLAG antibody (red), and the cone-
specific CRX target gene, CARR (green), in frozen retinal sagittal sections, 21 days following 
infection with rAAV5 GRK-hCRX.  C)  Fluorescent immunohistochemistry showing the 
expression of delivered mCrx mCherry shRNA, as determined by mCherry expression (red), the 
cone-specific CRX target gene, CARR (green), and the general cone marker PNA (white) in 
frozen retinal sagittal sections, 21 days following infection with rAAV5 mCrx shRNA.  Scale 
bars: 25µM.  D-I) Fluorescent macroscope images showing the expression of GFP in retinas of 
WT and -/- mice, 21 days following infection with rAAV5, rAAV2 triple Y-F or rAAV2 quadruple 
Y-F mutant viral capsids containing CBA (UF11)-Gfp viral constructs.  J-L) Fluorescent images 
of retinal sagittal sections showing the expression of GFP in WT, E168d2/+ and -/- mouse 
retinas, 21 days following infection with AAV2 triple Y-F containing a GRK-Gfp viral construct. 
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 While great progress has been made in the identification of the genetic causes of 
blindness, the lack of appropriate animal models has often greatly hampered our understanding 
of disease pathology and the underlying cellular mechanisms.  Such is the case for blinding 
diseases linked to mutations in gene CRX.  CRX is a retinal transcription factor that plays a 
critical role in regulating gene expression in photoreceptors.  Previous studies indicate that 
different disease causing CRX mutations distinctly alter the molecular function of CRX protein, 
falling into at least two functional groups.  The two primary classes of CRX mutant proteins are 
antimorphic c-terminal truncated proteins which actively impair target gene transcription and 
hypomorphic proteins with substitution mutations with reduced ability to bind DNA.  Antimorphic 
truncation mutations are associated with severe forms of dominant CoRD and LCA1–10, while 
hypomorphic substitution mutations are associated with less severe forms11–13.  A few specific 
substitution mutations maintain DNA-binding activity and are associated with more severe 
disease and are thought to be distinct from the hypomorphic group11,13.  The relationship 
between mutation type and disease severity lead us to the hypothesis that phenotypic variability 
was, at least in part, caused by mechanistically distinct groups of mutant CRX proteins.   
 To test this hypothesis, we selected two CRX mutations for further study as 
representative mutations for the two main groups: E168d2, which produces a truncated, 
antimorphic protein and is associated with severe dominant retinopathy, and R90W, which 
produces a hypomorphic protein with reduced DNA-binding and is associated with a mild 
dominant retinopathy.  We generated two Knock-IN mouse lines, Crx E168d2 and R90W.  We 
found that E168d2 and R90W mice accurately recapitulated their associated human 
phenotypes, establishing them as viable models for studying the pathobiology of CRX-
associated disease and supporting the hypothesis that mutation type influences disease 
severity.   
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 The phenotypes of E168d2 and R90W mouse retinas were characterized in detail by 
assessing retinal morphology, function and gene expression.  Homozygous E168d2/d2 and 
R90W/W mice both show incomplete maturation and progressive degeneration of 
photoreceptors, which did not form outer segments or establish physiological function.  
Expression of CRX target genes was more reduced in E168d2/d2 retinas, compared to 
R90W/W and Crx -/-, correlating with more rapid photoreceptor degeneration giving evidence 
that E168d2 protein has an antimorphic effect in vivo.  Heterozygous E168d2/+ had strong 
dominant phenotype with rapid photoreceptor degeneration occurring first in cones and reduced 
retinal function, while R90W/+ mice largely only had a mild deficit in retinal function at late ages.  
This suggests that distinct molecular defects in CRX protein cause different retinal phenotypes 
and likely account for much of the phenotypic variation in human patients.   
 Unexpectedly E168d2 mRNA and protein were overexpressed in E168d2 mouse retinas 
compared to WT Crx.  Since E168d2 protein was found to have antimorphic activity, the 
expression level could be an important genetic modifier of disease severity.  This prediction was 
tested by characterizing the phenotype of the mouse E168d2neo, which expresses the same 
E168d2 protein but at lower levels due to the inclusion of an intronic neo cassette.  
Heterozygous E168d2neo/+ mice had a dramatically less severe phenotype than E168d2/+ 
mice, demonstrating that mutant expression level is a critical modifier of phenotypic outcome.  
Expression profiling additionally showed that similar subsets of genes were affected in E168d2 
and E168d2neo mice but were slightly less severe in E168d2neo mice.  This showed that small 
changes in the expression of a large set of genes had a big impact on phenotypic outcome.  
The E168d2 and E168d2neo mice suggest that the truncated CRX protein E168d2 has 
antimorphic activity whose expression level directly affected phenotypic outcome. 
 It was unclear if the mutant protein overexpression phenotype of E168d2 mice was 
representative of a general characteristic of truncated CRX proteins or specific to this mutation.  
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A previous study in Drosophila had identified that another human CRX frameshift mutation, 
I138fs48, is overly stable14.  To investigate this further, the expression of Crx mRNA and protein 
in the CrxRdy feline model was assessed.  CrxRdy cat carry a frameshift mutation in an 
endogenous Crx allele, n.546delC, which was predicted to encode a truncated CRX protein just 
14 A.A. longer than E168d2.  CrxRdy cats expressed the truncated mutant Crx mRNA and 
protein at higher levels than WT Crx, similar to E168d2 mice.  This result showed that 
overexpression of mutant Crx was observed for two different truncation mutations and was even 
conserved between two species, suggesting a common mechanism.  Several human CRX 
truncation mutations were tested in vitro and were also found to be expressed at higher levels 
than WT CRX.  Collectively, these results demonstrate that several truncated CRX mutations 
were overexpressed suggesting a possible shared mechanism for mutations of this type.  This 
finding could have critical implications for understanding CRX-associated disease pathology, as 
mutant expression level was a strong genetic modifier of the E168d2 mouse phenotype. 
 To understand the nature of truncated Crx overexpression, the stability of WT and 
E168d2 mRNA was tested.  E168d2 mRNA was shown to be more stable than WT Crx both in 
vitro and in vivo in both heterozygous and homozygous mice.  These results link the 
overexpression of a truncated mutant Crx with altered mRNA stability.  Currently, experiments 
are being planned to determine whether altered mRNA stability is common between additional 
disease causing Crx mutations.  The stability of multiple forms of Crx can be assessed 
simultaneously in vitro using the barcoding technique first tested with WT and E168d2 (Fig 
4.2A-B).  Barcodes are being cloned into several human disease causing mutations to allow for 
the high throughput assessment of CRX mRNA stability.  Additionally, the use of Actinomycin D 
to generally block transcription could affect the natural mRNA degredation pathways yielding a 
result that is not truly representative of the in vivo state.  To improve upon these experiments, 
BrU-based mRNA labeling pulse-chase experiments, based on previous established 
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techniques15,16, are being designed to track the half-life of Crx mRNA under natural conditions.  
Finally, the specific mechanism of increased mRNA stability is currently unknown.  Further study 
to characterize the Crx sequence requirements and potential interacting proteins/RNAs will be 
necessary to begin to elucidate this mechanism.  It is also of interest to assess if altered mRNA 
stability is common among truncating mutations of other genes, namely homeobox family 
members, possibly indicative of a conserved mechanism. 
       The Crx E168d2 and R90W Knock-IN mice demonstrate the value of having 
mechanism-based true-to-disease animal models.  They improve upon current understanding of 
disease pathology in distinct forms of CRX-associated retinopathy and allow the identification of 
the underlying cellular pathways.  Phenotypic severity in these mice were associated with 
graded changes in the expression of similar sets of genes.  However, small changes in target 
gene expression level, as seen between E168d2 and E168d2neo mice, could have dramatic 
impact on phenotype, susceptibility to different stressors and effectiveness of therapeutic 
strategy.  The observation of mutant overexpression of E168d2 mRNA and protein and its link to 
altered mRNA stability identify a previously unknown characteristic of this CRX mutation, further 
demonstrating the utility of having human mutation based animal models.  The severe dominant 
retinal phenotype and shared mutant allele overexpression in the E168d2 mouse and the CrxRdy 
cat give strong evidence that these mutants cause disease through common mechanisms.  This 
both allows for the cross-validation of findings in each model and increases their utility as animal 
models for a larger group of disease causing mutations.  While these animal models surely do 
not serve as representative models for all forms of CRX-associated disease, their utility as 
accurate disease models clearly extend beyond their specific Crx mutation.   
 The availability of viable animal models for distinct forms of CRX-associated disease will 
allow for the development and testing of novel therapeutic strategies.  The E168d2 mouse and 
CrxRdy cat additionally provide matched small and large animal models.  Therapies found to be 
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effective in the mouse can be directly translated to the cat, increasing the utility of these studies.  
Previously, the efficacy of rAAV-mediated gene therapy and stem cell transplantation were 
tested in Crx KO mice with both approaches being successful in achieving modest gains in 
retinal morphology and function17,18.  However, the Crx KO mouse is not truly representative of 
human disease inheritance or pathology.  The E168d2 and E168d2neo mice demonstrate the 
importance of having accurate disease models.  These mice displayed differential susceptibility 
to light damage and effectiveness of 13-cis RAL treatment.  Therefore, the efficacy of drugs 
targeting the visual cycle could be highly context specific for CRX-associated diseases.  While 
targeting the visual cycle may have potential for protecting photoreceptors from degeneration, it 
will not improve retinal function in CRX-associated diseases.  rAAV-mediated CRX gene 
therapy approaches may currently have the most potential for rescuing retinal function for these 
diseases.  The emergence of retinal functional defects occurs before photoreceptor 
degeneration, suggesting a possible window for effective gene therapy.  The antimorphic activity 
of some Crx mutants may necessitate a combinatorial approach to remove the antimorphic 
effects and rescue gene function.  This can be achieved by combining Crx shRNA to 
knockdown endogenous gene expression with gene delivery of an shRNA resistant CRX.  
Preliminary evaluation of rAAV-mediated gene therapy shows that Crx shRNA and human CRX, 
which is Crx shRNA resistant, are effective at regulating downstream targets but that infection 
efficiency needs to be improved to have therapeutic benefit.  Further evaluation of rAAV 
serotypes and expression vectors need to be tested to optimize gene therapy approaches.     
 In conclusion, the generation and characterization of mechanistically distinct animal 
models have greatly improved our understanding of CRX-associated disease.  The phenotypic 
variation in human patients is, at least in part, driven by mutant proteins with different molecular 
properties.  Mutant proteins fall into functional groups reflective of their molecular activity and 
are associated with distinct forms of CRX disease.  We now have animal models which 
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accurately recapitulate many of these disease forms.  We have used these models to 
understand their unique pathologies and identify underlying disease mechanisms including the 
unexpected finding of mutant allele-specific overexpression of frameshift mutations due to 
increased mRNA stability.  These models demonstrate the importance of carefully and 
comprehensively designing and characterizing animal models to understand human disease.  
Our work will make it possible for the accurate testing of potential therapeutic strategies with the 
hope that these approaches could eventually by translated to human patients.    
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Appendix A - Materials and Methods 
 
Ethics statement 
All procedures involving mice were approved by the Animal Studies Committee of 
Washington University in St. Louis, and performed under Protocols # 20090359 and 20120246 
(to SC).  Experiments were carried out in strict accordance with recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health (Bethesda, MD),  
the Washington University Policy on the Use of Animals in Research; and the Guidelines for the 
Use of Animals in Visual Research of the Association for Research in Ophthalmology and Visual 
Science (http://www.arvo.org/animals/). Every effort was made to minimize the animals’ 
suffering, anxiety, and discomfort. 
 
Mice 
 Mice were housed in a barrier facility operated and maintained by the Division of 
Comparative Medicine of Washington University School of Medicine.  All mice used for 
experiments were backcrossed to C57BL6/J mice obtained from Jackson Laboratories (Bar 
Harbor, ME, Stock number 000664) for at least 5 generations.  Knock-IN of E168d2neo and 
R90Wneo were generated by the Mouse Genetics Core, Department of Ophthalmology and 
Visual Sciences, Washington University (Saint Louis, MO).  E168d2neo and R90Wneo 
constructs were transfected into 129Sv/J SCC#10 (ATCC SCRC-1020) embryonic stem cells 
and Knock-IN was achieved by homologous recombination into the endogenous mCrx locus 
and selected by neomycin.  The targeted ES cells were injected into C57BL6/J blastocysts to 
form chimeric Knock-IN E168d2neo and R90Wneo mice.  Germline transmission of E168d2neo 
and R90Wneo was identified by PCR genotyping and Sanger sequencing of genomic DNA from 
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F1 mice (Fig 2.1, Tran NM et al. PLOS Genetics 2013, Fig S1; Table 2.1).  Crx-/- mice were 
provided by Dr. Constance Cepko, Harvard University (Boston, MA). 
 
PCR Genotyping 
Genomic DNA was prepared from mouse tail tissue using the Gentra Puregene Tissue 
Kit (Qiagen).  PCR amplification was performed using Jumpstart RedTaq (Sigma-Aldrich).  
Primer sets (Table 2.1) are as follows: For all mice: neo (Neo-F/R) and Crx (Total Crx-F/R); for 
E168d2 colony: WT Crx allele (E168d2 WT-F, E168d2-R), E168d2 allele (E168d2 Mut-F, 
E168d2-R); for R90W colony: WT Crx allele (R90W WT-R, R90W-R), R90W allele (R90W Mut-
F, R90W-R).  
 
Sanger sequencing of genomic DNA 
Genomic DNA was prepared from mouse tail tissue using the Gentra Puregene Tissue 
Kit (Qiagen).  mCrx DNA was amplified by PCR using the Genomic mCrx Int/Ex4-F/R primer 
pair (Table 2.1).  Sanger sequencing was performed by the Protein and Nucleic Acid Chemistry 
Laboratory (Washington University, Saint Louis, MO) using the Sequencing primers E168 and 
R90W (Table 2.1) and Big Dye V3.1 (Advanced Biotechnologies). 
 
Electroretinogram  
At least 5 mice of each genotype were tested for ERG at 1mo, 3mo, or 6mo of age.  
Bilateral flash ERG measurements were performed using a UTAS-E3000 Visual 
Electrodiagnostic System running EM for Windows (LKC Technologies, Inc., Gaithersburg, MD) 
and recordings from the higher amplitude eye were used for analysis.  Mice were dark-adapted 
overnight, then anesthetized with 80 mg/kg ketamine and 15 mg/kg xylazine under dim red 
illumination for electrode placement and testing.  Body temperature was maintained at 37± 
0.5oC with a heating pad controlled by a rectal temperature probe (FHC Inc., Bowdoin, ME).  
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The mouse’s head was positioned just inside the opening of the Ganzfeld dome and pupils were 
dilated with 1.0% atropine sulfate (Bausch & Lomb, Tampa, FL).  The recording electrode was a 
platinum loop 2.0 mm in diameter, positioned in a drop of 1.25% hydroxypropyl methylcellulose 
(GONAK; Akorn Inc., Buffalo Grove, IL) on the corneal surface of each eye.  The reference 
needle electrode was inserted under the skin at the vertex of the skull. The ground electrode 
was inserted under the skin of the mouse’s back or tail.  The stimulus (trial) consisted of a brief, 
full-field flash (10 µs) either in darkness, or in the presence of dim (29.2 cd/mm) background 
illumination after 10 minutes adaptation time to the background light. The initiation of the flash 
was taken as time zero.  The response was recorded over 250 ms plus 25 ms of pre-trial 
baseline.  Responses from several trials were averaged.  For complete test parameters see 
Table S7 (Tran NM et al. PLOS Genetics 2013).  The log light intensity (log [cd*s/m
2]) was 
calculated based on the manufacturer’s calibrations.  The mean amplitudes (in microvolts) of the 
averaged dark-adapted A and B-waves and light-adapted B-waves were measured and 
quantified for comparison.  The between-group differences in peak amplitude were determined 
by testing genotype*flash intensity interactions (p<0.05, n≥5) at each age were compared using 
two-way ANOVA for repeated measurement data to account for potential correlations among 
readings from the same mice.  If the overall genotype*flash intensity interaction was significant, 
post-hoc multiple comparisons for differences between each genotype and the control group at 
each light intensity level were performed.  All the tests were two-tailed, significance: p<0.05.  
The statistical analysis was performed using SAS 9.3 (SAS Institutes, Cary, NC). p-values were 
adjusted for multiple comparisons by a permutation test using the default parameters provided 
in the LSMestimate statement in Proc Mixed.  Average percent reductions for each wave form 
were calculated by normalizing the peak amplitude of the mutant to WT and results were 
averaged for the flashes listed in Table 1; ±STDEV.   
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Immunohistochemistry and microscopy 
 For retinal sections: eyes were enucleated by removing the cornea and lens and fixed in 
4% paraformaldehyde for 24hrs at 4˚C.  A small corneal tag on the superior portion of the eye 
was used for orientation.  Eyes were embedded in paraffin and 5μM sagittal retinal sections 
were cut using a Leica RM 2255 microtome as previously described49.  Hemotoxylin and eosin 
immunohistochemistry was performed on sections for histology.  Fluorescent antibody 
immunostaining was performed using as previously described using 1% BSA/0.1% Triton X in 
1X PBS for blocking and antigen retrieval for all samples3,49.    
For whole flat-mounted retinas:  eyes were enucleated by removing the cornea and lens 
and fixed in 4% paraformaldehyde for 1hr at 4˚C.  Retinas were then dissected from the eye cup 
and 4 evenly spaced relief lines were cut (Fig 2.6A).  A scleral tag was left on the superior retina 
for orientation.  Retinas were mounted on poly-D lysine coated slides (Thermo Scientific), 
blocked with 1% BSA/0.1% Triton X in 1X PBS and immunostained as previous.   
Primary antibodies and dilutions used as follows:  Mouse monoclonal anti-CRX M02 
(1:200, Abova), rabbit anti-CRX 261 (1:200), rabbit anti-cone arrestin (CARR) (1:1000, 
Millipore), Rabbit anti-Opsin Red/Green (MOP) (1:1000, Millipore), Goat anti-OPN1SW (N-20) 
(SOP) (1:500, Santa Cruz), Mouse anti-Rhodopsin RET-P1 (RHO)(1:400, Chemicon), Peanut 
Agglutanin conjugated to Rhodamine (PNA)(1:500, Vector Labs).  Secondary Antibodies 
(1:400): Goat anti-rabbit or mouse IgG antibodies coupled to Alexa Fluor A488, Rhodamine 568 
or Cy2 647 (Molecular Probes) and Chicken anti-goat IgG (Molecular Probes).  All slides were 
counterstained with hard set DAPI (Vectashield), except when using Cy2 secondary, which 
were counterstained with Slow Fade Gold DAPI (Invitrogen).  All brightfield and fluorescent 
imaging was performed using an Olympus BX51 microscope and Spot RT3 Cooled Color Digital 
camera (Diagnostic instruments inc.).       
TUNEL analysis was performed using the Apoptag Fluorescein in situ Apoptosis 
Detection Kit (Millipore) per kit instructions.  TUNEL+ cells were counted in retinal sagittal 
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sections of P21 and P35 mice.  Significant differences from WT control (p<0.05) were 
determined by the Kruskal-Wallis rank order test, which was used to protect against departures 
from the normal distribution assumption.     
 
Morphometric ONL and Cone Analyses 
For ONL morphometry, 20x retinal composites of hematoxylin and eosin (H&E) stained 
sagittal sections were analyzed using Image J software (http://rsb.info.nih.gov/ij/).  The distance 
from the Optic Nerve (ON) was determined by drawing a curved line along the outer limiting 
membrane.  The ONL thickness was measured at 100μM, 500μM, 1000μM, and 1500μM from 
the ON and 200μM from the peripheral edge on both the superior and inferior retina.  Results 
are presented by ‘spider graph’.  The between-group differences in ONL thickness were 
determined by testing overall genotype*distance interactions (p<0.05, n≥3) at each age were 
tested using two-way ANOVA for repeated measurement data, followed by a post-hoc test to 
adjust p-value for multiple comparisons between each genotype and the WT control group at 
each distance using SAS 9.3 (SAS Institutes, Cary, NC), as above.   
 Cone nuclear localization was determined by immunostaining retinal sections with 
CARR.  The ONL was divided into 3 equally sized zones (OONL, MONL, IONL; Fig 5A) on 20x 
retinal composite images using Image J software (http://rsb.info.nih.gov/ij/) and the cone nuclei 
within in each zone from three sections for each mouse were counted.  Significant differences 
from WT for each zone were determined by Kruskal-Wallis rank order test (p<0.05, n≥3)   
For cone density and opsin expression assessment, 10 images at 40x magnification of 
whole flat-mounted retinas were taken in the zones specified in Fig 2.6A.  All peripheral images 
were taken ~400µM from the edge of the retina and the central image was taken ~250µM from 
the ON along the lateral axis.  Cones were counted within a 200x200µM square grid for each 
image using Image J software and the density of cones/(mm2*1000) was calculated.  The 
between-group differences in cone density were determined by testing overall genotype*retinal 
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region interactions (p<0.05, n≥3) at each age were tested using two-way ANOVA for repeated 
measurement data, followed by a post-hoc test to adjust p-value for multiple comparisons 
between each genotype and the WT control group in each retinal region using SAS 9.3 (SAS 
Institutes, Cary, NC), as above.  For regional cone opsin expression analysis (Fig 2.8E-P), 
differences in the fraction of cones expressing SOP, MOP, SOP/MOP or no opsin was tested in 
each region using a Kruskal-Wallis rank order test (p<0.05).  
 
Transmission Electron Microscopy (TEM) 
For TEM studies, eyes were enucleated by removing the cornea and lens and fixed in 
2% paraformaldehyde/3% gluteraldehyde in 0.1 M phosphate buffer (pH 7.35) for 24 hrs, post-
fixed in 1% osmium tetroxide for 1 hr and stained en bloc with 1% uranyl acetate in 0.1 M 
acetate buffer for 1 hr.  Blocks were then dehydrated in a graded series of acetones and 
embedded in Araldite 6005/EMbed 812 resin (Electron Microscopy Sciences).  Semi-thin 
sections (0.5-1µm) were cut through the entire retina at the level of the optic nerve and stained 
with toluidine blue, post-stained with uranyl acetate and lead citrate, viewed on a Hitachi H7500 
electron microscope and documented in digital images.  Three retinas for each genotype were 
sampled at P21 at 800-1200μM from the optic nerve.  ≥10 images of four key features were 
collected by random sampling: OS-RPE (10000x), OS-IS (12000x), ONL (5000x), OPL 
(10000x).  Images were analyzed in a blinded manner using Image J software. 
 The nuclear percent area of heterochromatin was measured using Image J software in a 
randomized blinded analysis.  For each genotype, 10 5000x images of the ONL were taken for 
three mouse retinas.  For each image, 10 rod nuclei were randomly selected for analysis.  The 
rod nucleus was outlined using the segmented polygon tool, electron dense regions of the 
nuclei associated with heterochromatin were thresholded and the percentage of the area above 
the threshold was measured.  Thresholding was variably adjusted to accommodate for 
differences in brightness and contrast.  The between-group differences were compared using 
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one-way ANOVA for repeated measurement data, to account for potential correlations among 
photos from the same mouse.  All the tests were two-tailed, significance: p<0.05 (n=3).  The 
statistical analysis was performed using SAS 9.3 (SAS Institutes, Cary, NC).  The overall test for 
genotype difference was statistically significant (p=0.02), therefore E168d2/+ and E168d2neo/+ 
were compared to WT Fig 2.6).         
 
Transient transfection assays 
HEK293 cells (ATCC© CRL-11268) were cultured on 60mm plates in Dulbucco’s 
minimum essential media (DMEM) with 10% fetal bovine serum and Penicillin/Streptomycin.   
Cells in 60% confluence were transfected with pCAGIG-NRL and pCAGIG-hCRX WT, E168d2 
and R90W either alone or in combination using CaCl (0.25M) and Boric Acid Buffered Saline 
(1x) pH 6.75 as previously described3.  Cells were harvested 48 hours post transfection for 
either RNA (PerfectPure RNA tissue kit, 5Prime), protein (NePER nuclear and cytoplasmic 
extractions reagents, Thermo Scientific), or Dual-luciferase assays.  Dual-luciferase assays 
were performed as previously described3.  Significant differences from pcDNA3.1hisc control 
were determined by Kruskall-Wallis rank order test (p<0.05; n=3).  Post-hoc comparisons (Fig 
2.10 D&E; indicated by brackets) were tested using a less conservative FDR p-value method for 
multiple comparisons using PROC Multtest of SAS (V9.3).  FDR p<0.09 was considered 
marginally significant.   
      
Western Blot assays 
 Whole retina protein lysates were prepared by homogenization of four genotype-
matched isolated whole retinas from P10 mice and lysis in 1x RIPA buffer (Sigma) for 10min 
with protease inhibitors (Aprotinin, Leupeptin, peptistatin, 0.1mM Phenylmethaneslfonyl 
fluoride). Nuclear lysates were prepared using NE-PER Nuclear and Cytoplasmic Extraction 
Reagants (Thermo Scientific) with protease inhibitors.  Either 30μg of whole protein lysate or 
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5μg of nuclear protein lysate was boiled for 10min.  Samples were run on a 4-11% SDS-PAGE 
gel and transferred onto Transblot Turbo nitrocellulose membranes (Bio-Rad) using the 
Transblot Turbo system (Bio-Rad).  Membranes were probed with Rabbit anti-CRX 119b1 
(1:750) and Mouse anti-β-Actin (Sigma)(1:1000).  Goat anti-Mouse IRDye 680LT and Goat anti-
Rabbit IRDye 800CW (LI-COR) were used as secondary antibodies.  Signal was detected and 
quantified using the Odyssey Infrared Imager (LI-COR) and associated manufactory software. 
Kruskal-Wallis rank order test (Proc Npar1way of SAS, V9.3) was used to test for an overall 
difference among genotypes (p=0.0002), then each genotype was compared to WT control 
(p<0.05).  Post-hoc analyses were performed using FDR p methods for multiple comparisons 
using PROC Multtest of SAS (V9.3) (FDR p<0.09) (n≥3).     
 
qRT-PCR          
RNA was extracted from whole retinas of one male and one female mouse at either P10 
or P21 for each biological replicate using the PerfectPure RNA tissue kit (5Prime).  RNA was 
quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). cDNA was synthesized from 1μg of RNA using the Transcriptor First Strand 
cDNA Synthesis kit (Roche Applied Science).  A 10μl QRT-PCR reaction mixture containing 1x 
EvaGreen with Low Rox reaction mix (BioRad), 1μM primer mix, and diluted cDNA was 
prepared and run on a two-step 40 cycle amplification protocol with melt curve determination on 
a BioRad CFX thermocycler in triplicate.  The Cq’s of technical replicates were averaged and 
the results were analyzed using the Delta Cq method in QBase software (Biogazelle).  Primer 
sets (Tran NM et al. PLOS Genetics 2013, Table S1) were designed using MacVector software 
and synthesized by IDT DNA technologies.  For mCrx allele specific amplification the following 
primers were used: for E168d2 and E168d2neo mice: WT allele specific- Crx E168d2 WT 
RTF/R, total- Crx R90W WT-RTF/R; for R90W and R90Wneo mice: WT allele specific- Crx 
R90W WT-RTF/R, total Crx E168d2 WT RTF/R (Fig 2.2J), Relative gene expression was 
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normalized to Ubb and Tuba1b.  Kruskal-Wallis rank order test (Proc Npar1way of SAS, V9.3) 
was used to test for an overall difference among genotypes (p<0.05; n≥3).  Post hoc analyses 
were adjusted for multiple comparisons using FDR p methods, as above (FDR p≤0.09).  
 
Electrophoretic mobility shift assays (EMSA) 
BAT-1 and BAT-1 mutated AB probes 5' end-labeled with 700 IRDye were synthesized 
by Integrated DNA Technologies (IDT).  Nuclear protein extracts from HEK293 cells (~1x108 
cells) transfected with pCAGIG-hCRX, pCAGIG-hCRX E168d2, or pCAGIG-hCRX R90W were 
prepared following NE-PER kit instructions (Thermo Scientific).  Nuclear extracts were tested for 
CRX expression by running on a Western Blot as above (Fig 2.8B).  CRX levels were quantified 
by normalizing to β-Actin (Sigma) and a 2-fold dilution series of equivalent amounts of CRX WT, 
CRX[E168d2] and CRX[R90W] protein were used for binding reactions.  Binding reactions were 
performed using the Odyssey Infrared EMSA kit (LI-COR), per kit instructions using 1μg of 
nuclear protein extract and 50nM IRDye labeled oligo.  Samples were run on a native 5% 
polyacrylamide; 0.5x Tris/Borate/Ethylenediaminetetraacetic acid (EDTA) buffered gel and 
imaged on the Odyssey Infrared Imager (LI-COR).   
 
Chromatin immunoprecipitation (ChIP) assays  
ChIP was performed as previously described3,5,50.  Basically, 6 retinas per sample were 
dissected and chromatin was cross-linked with 1% formaldehyde in PBS for one minute at room 
temperature.  After cell lysis and chromatin fragmentation by sonication, chromatin fragments 
were immunoprecipitated with the CRX 119b-1 antibody5 or normal rabbit IgG (Santa Cruz) 
bound to Protein A beads (GE Healthcare Life Sciences, Piscataway, NJ).  After extensive 
washing, the immunoprecipitated chromatin was eluted with 50mM NaHCO3 1% SDS, heated to 
67oC to reverse the cross-links, the DNA purified by ethanol precipitation and analyzed by PCR 
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with gene-specific primers (Table 2.1) (n≥3).  Fold enrichment was determined by quantitative 
ChIP PCR.  Critical threshold (Ct) values for CRX and IgG immunoprecipitation (IP) were 
normalized to input and mock subtracted.  The fold enrichment of CRX:IgG was calculated 
based on the formula shown below.  Significant enrichment was determined by testing overall 
promoter*genotype interactions by two-way ANOVA for repeated measures using SAS 9.3 (SAS 
Institutes, Cary, NC) (p<0.05, n=3), as above. 
 
∆Ct= (Ct[CRX or IgG]-Ct[Input]) 
∆∆Ct= ∆Ct[CRX or IgG]- ∆Ct[mock] 
Fold enrichment= ((2-∆∆Ct CRX)/(2-∆∆Ct IgG) 
 
Microarray 
Triplicate RNA samples were prepared from 4 pooled retinas from 1 male and 1 female 
mouse at P10 for WT and homozygous E168d2neo, R90Wneo and -/- mice using the 
PerfectPure RNA Tissue Kit (5 Prime).  The RNA was fluorescent labeled and hybridized to 
MouseWG-6 v2.0 Expression Beadchips (Illumina) by Washington University Genome 
Technology Access Center (GTAC).  The raw microarray datasets are available at the NCBI 
GRO website (http://www.ncbi.nlm.nih.gov/gds, access number: GSE51184).  Microarray data 
were analyzed using significance analysis of microarrays (SAM) following background 
subtraction and quantile normalization in Illumina Genome Studio platform.  Control probes and 
probes with detection p-value <0.05 across all samples were removed prior to any analysis. 
Candidate probes with 2.0-fold disregulation at false discovery rate ≤0.05 from each comparison 
were chosen for further analysis.  Cellular processes associated with differentially expressed 
genes were assigned based on gene ontology provided by Mouse Genome Informatics 
(http://www.informatics.jax.org/). 
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Next-generation RNA-Seq 
 Triplicate RNA samples were prepared from 4 pooled retinas from 1 male and 1 female 
mouse at P10 for WT, E168d2/d2, R90W/W, E168d2/+, E168d2neo/+, R90W/+ and P21 WT, 
E168d2/+, E168d2neo/+ and R90W/+ mice using the PerfectPure RNA Tissue Kit (5 Prime).  
Total RNA was processed by GTAC using standard protocol and sequenced on the Illumina 
HiSeq. 1x42bp reads were aligned to the mouse genome (version mm9) with the sequence 
aligner TopHat. The HTSeq package was used to assign aligned reads to the gene annotation 
reference track (UCSC Genes). This generated a raw read count per gene which was used in 
EdgeR(v3.2.4) for detecting differentially expressed genes. For each of the genotype 
comparisons, genes that did not pass the filter criteria of CPM (Counts Per Million) >=5 in all 
replicates of at least one comparison group were removed prior to the analysis. Filtered count 
data was normalized by the EdgeR default normalization method, TMM, and differential 
expression analysis for each of the comparison groups were performed by the exact test. P-
values were subjected to Bonferroni and Hochberg multiple testing correction to include false 
discovery rate (FDR). Downstream analysis was performed using custom perl and R scripts. 
Heatmaps were generated using the heatmap.2 function of the gplots R package. 
 
Actinomycin D treatment 
 in vitro: Crx WT and E168d2 constructs tagged distinct barcodes (Table 4.1) were co-
transfected in pairs into HEK 293 cells and cultured, as previously described.  Constructs 
carrying common barcodes were not co-transfected.  After 48hrs, transfected cells were treated 
with 10mg/ml Actinomycin D (Sigma-Aldrich) diluted in DMSO, which blocks mRNA 
transcription8–11.  Cell were incubated and then harvested at 4hrs and 8hrs.  mRNA was 
collected, as previously described, and the expression of Crx mRNA was determined by qRT-
Appendix A - Materials and Methods 
 
159 
 
PCR and normalized to Ubb and Gapdh expression, results shown are the fold-change relative 
to expression level at time 0hrs.  
 ex vivo: Retinas were dissected at the same time and incubated in 6-well cell culture 
plates for 12hrs in 2ml explant media:  1:1 DMEM (Gibco):Ham's F12 (Gibco), 10%FBS, 100U 
Penicillin, 100mg/ml Strepomycin, 2mM L-Glutamine and 5µg/ml Insulin.  10mg/ml of 
Actinomycin D (Sigma) diluted in DMSO was added to the 8hr samples.  At 4hrs, 10mg/ml of 
Actinomycin D was added to the 4hr samples and 8hr retinas were moved to fresh wells 
containing actinomycin.  At 8hrs, retinas were placed in 400μl RNAlater (Qiagen), then prepared 
and analyzed by qRT-PCR as previously described. 
 
Light damage (LD) and 13-cis RA treatments 
 For light treatments, mice were dark adapted overnight.  Eyes were dilated with 1% 
Cyclogyl and 2.5% Phenylphrine Hydrochloride and placed in darkness 30min before light 
damage.  LD was performed in a temperature controlled rat cage with the top removed and 
lined with reflective material to give an even distribution of light treatment.  Treatment was 
performed using white fluorescencent light and the intensity was measured using a photometer.  
Light intensity was 11-13.5KLUX for all experiments.  Mice were placed into 6 separate cages 
containing moistened food pellets and each receiving light treatments of even intensity for 8hrs.  
Mouse pupils were re-dilated every 2 hours.  For 13-cis RA treatments, 13-cis RA (Sigma-
Aldrich) was reconstituted in DMSO to a concentration of 0.013mg/µl.  40mg/kg 13-cis RA was 
injected into the mouse's interperitoneal cavity 12hrs before LD and mice were dark-adapted 
overnight.  Mice were redosed with 40mg/kg 13-cis RA 30min before LD.  Following all LD 
experiments, mice were returned to a 12hr light-dark cycle under normal ambient light 
Appendix A - Materials and Methods 
 
160 
 
conditions (~100LUX) for 7 days.  After 7 days, retinal function was tested by ERG and eyes 
were collected for histology, as previously described. 
 
rAAV-mediated gene therapy 
   3xFLAG-tagged human CRX or shRNA targeting mouse Crx were subcloned into viral 
vector plasmids with expression driven from the photoreceptor specific Rhodopsin Kinase 
(GRK)30 or ubiquitous CBA (U11)31 promoters.  Viral vector plasmid constructs were packaged 
into rAAV serotypes 2, 5, 8, 8/9, 2 triple Y-F and 2 quad Y-F, which were shown to have 
different infection characteristics in photoreceptors30–32.  All viral vectors were packaged, 
purified, and titered according to previously described methods31,33,34.  A titer of 1e1011-12 of virus 
was injected into the sub-retinal space of P0-P3 mouse eyes in a barrier facility using a 32-
guage hamilton syringe.  Mice were housed in a barrier-facility for 14days-1mo and then 
sacked.  Eyes were collected, and the sclera was removed for imaging.  Eyes were imaged for 
Gfp using a Leica Macrofluor macroscope and embedded in OCT (BD Sciences).  10µM retinal 
sagittal sections were cut using a Cryostat and mounted on polysine-coated slides (Fisher) and 
stained using previously described protocols.  3xFLAG-tagged human CRX expression was 
detected using a monoclonal FLAG antibody (Sigma-Aldrich). 
 
 
 
